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Abstract 
 
The number of older people at risk of developing dementia is growing rapidly 
worldwide, and Alzheimer’s disease (AD) represents the most common cause of 
dementia in the elderly. The principal characteristics of AD include the presence of 
amyloid plaques, neurofibrillary tangles, brain atrophy in specific brain areas and loss 
of the neurotransmitter acetylcholine (ACh), which is hydrolysed by the 
cholinesterases (ChE) acetylcholinesterase (AChE) and secondly by 
butyrilcholinesterase (BChE). 
Pharmacological treatments currently used to alleviate AD symptoms include ChE 
inhibitors, but they exhibit bioavailability problems and side effects like hepatotoxicity 
and gastrointestinal disorders. Thus, there is a high interest in finding better ChE 
inhibitors from natural sources.   
 
Due to the high oxygen consumption and lipid content, the central nervous system 
(CNS) is more sensitive to oxidative stress compared to other parts of our body. Thus, 
special interest has been assigned in nutritional antioxidants and metal chelation 
therapy as viable neuroprotective approaches for neurodegenerative disorders.  
 
Marine organisms are recognized as rich sources of novel biologically active 
compounds. However, its application in the treatment of neurological disorders is still 
scarcely explored. In this context, the main goal of this study was to evaluate the AChE 
and BChE inhibitory activity of methanol extracts made from different species of 
macro- and microalgae, seagrasses and halophytes, as well as evaluate their chelating 
activity on iron (Fe2+) and copper (Cu2+) ions.   
 
The most active species against both enzymes were the brown macroalgae Cystoseira 
compressa, C. nodicaulis and C. tamariscifolia and the halophytes Carpobrotus edulis 
and Frankenia laevis.  
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The chelating activity was higher for Cu2+ than for Fe2+ in the majority of the species 
tested, being the most active the red macroalgae Plocamium cartilageneum. These 
species are thus promising candidates for more detailed in vitro and in vivo studies 
aiming their use as sources of innovative products with neuroprotective aplications.  
 
Keywords: Alzheimer’s disease; metal chelation; acetylcholinesterase; 
butyrylcholinesterase; marine natural resources; neuroprotection.    
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Resumo 
 
O número de pessoas idosas em risco de desenvolver demência cresce rapidamente 
em todo o mundo e o Alzheimer representa a causa mais comum desta forma de 
distúrbio. Esta é uma doença que se caracteriza pela presença de microplacas senis, 
emaranhados neurofibrilares, atrofia do cérebro em áreas específicas e perda do 
neurotransmissor acetilcolina (ACh), que é hidrolisado principalmente pela 
acetilcolinesterase (AChE) e, numa segunda instância pela butirilcolinesterase (BChE).  
Os tratamentos farmacológicos mais usados actualmente, para o alívio dos sintomas 
do Alzheimer, incluem inibidores de AChE e BChE, mas devido a problemas de 
disponibilidade biológica e efeitos colaterais como hepatotoxicidade e desordens 
gastrointestinais dos medicamentos comummente utilizados existe um grande 
interesse em encontrar inibidores destas enzimas a partir de recursos naturais. 
 
Devido ao consumo de oxigénio e ao alto teor de lípidos, o sistema nervoso central 
(SNC) é mais propício a sofrer stress oxidativo em comparação com outras partes do 
corpo. Assim, enquanto potenciais métodos de neuroproteção, especial interesse tem 
sido atribuído a antioxidantes nutricionais e terapia de quelação de metais de 
transição, como o ferro e o cobre, formando complexos inactivos e evitando a 
formação dos prejudiciais radicais livres.  
 
Os organismos marinhos têm provado, devido à produção de metabolitos secundários, 
ser fontes riquíssimas de novos compostos biologicamente activos e sem efeitos 
colaterais. No entanto, a sua aplicação no tratamento de distúrbios neurológicos ainda 
é pouco explorada e, portanto, o principal propósito deste estudo foi testar a 
capacidade inibidora da AChE e BChE de extratos metanólicos feitos a partir de 
diferentes algas, ervas marinhas e plantas halófitas disponíveis na costa sul do Algarve 
(Portugal), bem como avaliar o seu poder quelante em iões ferro (Fe2+) e cobre (Cu2+). 
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As espécies mais activas na inibição de ambas as enzimas foram as macroalgas 
castanhas Cystoseira compressa, C. nodicaulis e C. tamariscifolia e as halófitas 
Carpobrotus edulis e Frankenia laevis. A actividade quelante foi maior para o Cu2+ do 
que para o Fe2+ na maioria dos casos, sendo a espécie mais activa a macroalga 
vermelha, Plocamium cartilageneum. Estas espécies são, portanto, promissoras 
candidatas a novos e mais detalhados estudos in vitro e in vivo, visando o seu uso 
como fonte de inovadores produtos com aplicações neuroprotetoras. 
  
Palavras-chave: Alzheimer; actividade quelante; acetilcolinesterase; 
butirilcolinesterase; recursos naturais marinhos; neuroproteção. 
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1. INTRODUCTION 
 
This section begins with a definition of Alzheimer’s disease and its characteristics, 
followed by information on cholinergic theory and chelating activity. 
Is also contains some information about the marine natural resources used in this 
study, such as main components and uses. Finally, the purpose and motivation for 
conducting this thesis is presented. 
 
1.1. Alzheimer’s disease (AD) 
1.2. Marine natural resources          1.3. Objective 
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1.1. Alzheimer’s disease (AD) 
 
Dementia (in Latin: irrationality) is a group of symptoms that may accompany 
neurological disorders or conditions, appears usually in the elderly and  affects 
important daily living skills such as memory, thinking, comprehension, calculation and 
language (Holden & Kelly, 2002). It affects approximately 47 million people worldwide, 
the maiority of them in developing countries and it is estimated that this number could 
increase to 131 million by 2050 (Alzheimer’s Disease International, 2015). The 
commonest causes of dementia are Alzheimer’s disease (AD), Parkinson disease (PD), 
Dementia with Lewy Bodies and Myasthenia gravis (Holden & Kelly, 2002).    
 
AD was first identified in 1906 by Alois Alzheimer, a German psychiatrist and 
neuropathologist, but only in the last 40 years research has revealed more about its 
causes and possible treatments (Zarotsky et al., 2003). However, despite the research 
in recent years, its exact cause(s) still remains to be clarified (Zarotsky et al., 2003).  
Nowadays, AD is considered the fourth leading cause of death in developed nations 
(after heart disease, cancer and strokes) and is characterized by the presence of 
amyloid plaques, neurofibrillary tangles, neuronal and synaptic loss and brain atrophy 
in specific brain areas (Natarajan et al., 2009).  
 
1.1.1. Symptoms  
 
The difficulty to process and remember new information is perhaps the most 
common symptom in patients with AD, due to the fact this is a disease begins affecting 
areas of the brain responsible for forming new memories. As the disease progresses 
from mild to moderate and severe, the damage increases and other cognitive and 
functional capacities are affected, such as:  memory loss that disrupts daily life; 
difficulties in planning or solving daily problems; difficulty in the completion of familiar 
tasks at home, work or at leisure; confusion with time or place; trouble understanding 
visual images and spatial relationships; misplacing things and losing the ability to 
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retrace steps; decreased or poor judgment; withdrawal from work or social activities; 
changes in mood and personality; aphasia (problems with words in speaking or 
writing); apraxia (loss of the ability to execute or carry out learned purposeful 
movements) and agnosia (failure to recognize objects). 
 
In very advanced stages of the disease, people need more care in their day 
living, becoming increasingly dependent and losing the ability to communicate and 
recognize relatives. Because of its fragility, the patient becomes increasingly vulnerable 
to infections, including pneumonia and this can cause ultimately, death.   
 
 
1.1.2. Causes of AD  
 
Although the exact cause of AD is still unknown, it is believed that this disease 
develops due to a number of factors, including complex alterations in chemical and 
electrical processes that take place within the brain.    
A normal healthy brain contains billions of neurons, constantly receiveing 
information from each other in the form of electrical charges travelling down the axon 
to the end of the neuron – neurotransmitters, which move across microscopic gaps, or 
synapses, between neurons (Rodgers, 2008). They bind to receptor sites on the 
dendrites of the next neuron (Fig. 1.1) and AD is the responsible for the disruption of 
the neuronal network, causing the destruction of memory and thinking skills over time 
(Rodgers, 2008).     
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Figure 1.1 Neuronal network in a healthy brain (Rodgers, 2008).  
 
AD is associated with inflammatory processes (Stuchbury and Munch, 2005). 
Abnormal structures called β-amyloid plaques (outside the neurons) and 
neurofibrillary tangles (inside the neurons) are classic biological hallmarks of the 
disease and can induce inflammation (Ferreira et al., 2006): 
 
 Plaques form with the extracellular β-amyloid peptides accumulation as well as 
dystrophic neurites, reactive astrocytes, phagocytic cells and protein fragments 
derived from degenerating cells or liberated from neurons (Jalbert et al., 2008).   
β-amyloid are fragments, result of amyloid precursor protein (APP) cleavage by β-
secretase, α-secretase and γ-secretase (Brewer, 2007). These fragments increase in 
size and become insoluble and consequently toxic, contributing to cell death (Fig. 
1.2) (Brewer, 2007).    
 
 Neurofibrillary tangles are made when tau protein separates from microtubules, 
which are used in a normal brain to stabilize critical structures to the cell's internal 
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nutrients transport system, causing neurotransmitter deficits and neuronal cell 
death (Jalbert et al., 2008). Tau strands aggregate inside the neurons, forming 
tangles and, therefore, disable the transport system and destroy the cell (Fig. 1.3) 
(Brewer, 2007).      
 
 
Figure 1.2 Formation of β-amyloid plaques (a, b) (Rodgers, 2008).  
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Figure 1.3 General aspect of a healthy neuron (a) and a diseased neuron, exhibiting the 
formation of tau tangles (b) (Rodgers, 2008). 
 
Although many events that happen in the brain of patients with AD are well 
known, there are still many unclear factors such as what other changes are taking 
place in the aging brain and its cells and what influence do other diseases, genetics, 
and lifestyle factors have on the risk of developing AD as the brain and body age 
(Rodgers, 2008).  
 
1.1.3. Risk Factors for AD 
 
1.1.3.1. Advanced age  
People younger than 65 years can develop AD, but the risk increases after this 
age (Geldmacher, 2010).   
 
1.1.3.2. Family history  
Individuals who do not have a first-degree relative with AD are less likely to 
develop it than those who have and the risk becomes higher when the individual has 
more than one first-degree relative with AD (Huang et al., 2004).  
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1.1.3.3. Apolipoprotein E-ε4 (APOE-ε4) 
A genetic factor in late-onset Alzheimer’s disease is APOE-ε4, which is one of 
three common forms (ε2, ε3 and ε4) of the APOE gene, responsible for providing the 
blueprint for a protein that carries cholesterol in the bloodstream (Jalbert et al., 2008). 
Everyone inherits one form of the APOE gene from each parent, but those who inherit 
the form APOE-ε4 have increased risk of developing AD in an earlier age (Jalbert et al., 
2008). The risk can also increase if the individual inherits two APOE-ε4 genes, but this 
does not guarantee the development of AD (Jalbert et al., 2008).    
On the other hand, APOE-ε4 which has an arginine at position 112 rather than a 
cysteine, while the other apolipoprotein alleles have cysteine at this position 
(Reynolds, 1997), may be involved in copper binding and to the diminished antioxidant 
effect of the E-4 allele (Brewer, 2007).  
 
1.1.3.4. Cardiovascular Disease Risk Factors  
The cardiovascular diseases that offer a major risk in developing AD are 
associated with high cholesterol (especially in midlife), Type 2 diabetes, high blood 
pressure (especially in midlife), physical inactivity, smoking and obesity (Geldmacher, 
2010). Thus, remaining mentally and physically active and consuming a diet low in 
saturated fats and rich in vegetables, may support heart and brain health (Geldmacher, 
2010).    
 
1.1.4. The Cholinergic theory   
 
The cholinergic system is composed by a set of cells that produce and/or are 
stimulated by the neurotransmitter acetylcholine (ACh) and control the central 
nervous system (CNS) functions (Gibbs, 2010). ACh is released to travel across the 
synaptic cleft and the two types of receptors, muscarinic and nicotinic (post-synaptic 
terminal), respond to ACh, facilitating intracellular communication, memory processing 
and higher cognitive functions (Fig. 1.4) (Gibbs, 2010). Acetylcholinesterase (AChE) is 
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the main enzyme that hydrolyzes ACh into a choline and an acetyl groups (Ferreira et 
al., 2006).    
 
 
Figure 1.4 Actuation of acetylcholinesterase in a neurotransmission signaled by 
acetylcholine – After signalling, acetylcholine is released from receptors and broken 
down by AChE to be recycled in a continuous process. Source: www.vrp.com/brain-
health. 
 
 
The basal forebrain is the brain area where declines in the level of ACh in AD 
patients can be found and the projection to the hippocampus and neocortex lead to 
impairments in memory and cognitive functions (Zarotsky et al., 2003; Natarajan et al., 
2009). 
Acetyltransferase is needed for the synthesis of acetylcholine, and its activity 
can be reduced up to 90%, as a result of the loss of cholinergic neurons (Zarotsky et al., 
2003). 
Treatment strategies have therefore focused on replacing the level of ACh, 
enhancing cholinergic activity in the affected regions of the brain, or inhibiting AChE 
action, avoiding its degradation (Zarotsky et al., 2003; Natarajan et al., 2009). However 
this current treatment does not halt the progression of AD, but contribute to modest 
improvements in memory, thinking and reasoning skills (Zarotsky et al., 2003; 
Natarajan et al., 2009).   
 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 9 
The first organophosphate AChE inhibitor was synthesized in the 1850s and in 
the 1930s synthetic cholinesterase inhibitors, such as neostigmine, began to be used to 
treat autonomic nervous system manifestations (Taylor, 1998).   
AChE inhibitors not only increase the level of ACh but also prevent the 
formation of β-amyloid plaques, activating secretase, which acts on amyloid precursor 
protein thereby preventing neuronal death due to inflammation in AD (Natarajan et 
al., 2009). 
 
The mammalian brain contains two cholinesterases, AChE and 
butyrylcholinesterase (BChE) (Kuhl et al., 2006). Butylcholines are not physiological 
substrates in the brain, and, although their function remains unclear, it has been found 
to increase progressively in patients with AD. In the human brain, BChE is found in 
neurons and glial cells, as well as in plaques and neurofibrillary tangles in patients with 
AD (Zarotsky et al., 2003). So, it is believed that after AChE, BChE plays an important 
role in the inhibition of ACh (Orhan et al., 2004). Until now, there are no drugs that 
inhibit BChE as strongly as AChE (Orhan et al., 2004).  
 
 
1.1.5. Oxidative stress and metal accumulation  
  
Oxidative stress (OS) and the hypothesis that brain metal dysregulation, 
resulting in reactive oxygen species (ROS) generation from H2O2 and inflammatory 
processes, plays a pivotal role in different clinical disorders, such as 
neurodegeneration, diabetes, hypothyroidism, liver failure, atherosclerosis, ischemia 
reperfusion injury, cancer and cardiovascular diseases (e.g. stroke or thalassemia) 
(Conforti et al., 2009; Weinreb et al., 2009). OS triggers a cascade of events leading to 
apoptotic/necrotic cell death in neurodegenerative disorders, such as AD, PD, 
Huntington’s disease and amyotrophic lateral sclerosis (Zecca et al., 2004; Tirosh et al., 
2007; Ebrahimzadeh et al., 2008). Moreover, due to the high oxygen consumption and 
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lipid content, the CNS is more sensitive to oxidative stress compared to other parts of 
our body (Pangestuti & Kim, 2011).   
Free radicals, which are generated in mitochondria (Fig. 1.5) can help cells to 
fight infections, but can also damage the neuron’s cell membrane or DNA, because 
they are very reactive and easily react with other molecules (Rodgers, 2008).   
 
 
Figure 1.5 Oxidative Stress and mitochondria – The arrows indicate the movement of 
free radicals, which can spread easily from damaged mitochondria to other parts of the 
cell (Rodgers, 2008). 
 
1.1.5.1. Iron and AD 
Iron is involved in several processes (El & Karakaya, 2004; Zecca et al., 2004), such as: 
 transport, storage and activation of oxygen (as a central element of the heme 
molecule, which is a critical part of haemoglobin); 
 respiration; 
 activity of several enzymes, including cytochromes, which acts in electron 
transport or tyrosine hydroxylase, which is required for dopamine synthesis; 
 synthesis of steroid hormones and bile acids;  
 detoxification of external substances in the liver and signal controlling in some 
neurotransmitters, like dopamine and serotonin systems in the brain.   
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However, when iron homeostasis is not well regulated it can degrade lipids, 
proteins and cells as for example astrocytes, microglia or neurons, due to unwanted 
oxidative reactions (Rival et al., 2001; Zecca et al., 2004; El & Karakaya, 2004). The 
excess iron, derived from the breakdown of transfused red blood cells, is deposited as 
hemosiderin and ferritin in the liver, spleen, endocrine organs and myocardium 
(Ebrahimzadeh et al., 2008).   
Consequently, there is increasing evidence that iron accumulation in the brain with 
age can cause, as mentioned above, a vast range of disorders to the CNS (Zecca et al., 
2004).   
There are two classes of iron-related neurodegenerative disorders (Zecca et al., 
2004): 
- Those resulting from iron accumulation in specific brain regions; 
- Those resulting from deficiency in iron metabolism and/or homeostasis.  
 
In these disorders are usually involved protein modification, misfolding and 
aggregation, causing the formation of the intracellular inclusion bodies that are the 
postmortem characteristics of many neurodegenerative diseases, like AD and PD 
(Zecca et al., 2004).  
Iron might also have a direct impact on plaque formation, due to its action as a 
modulator of α-secretase in APP cleavage (Huang et al. 2000; Rodgers et al., 2002; 
Kawahara, 2003; Zecca et al., 2004), although some authors argue that by binding iron, 
β-amyloid might, in fact, protect the surrounding neurons from OS (Zecca et al., 2004). 
Iron is also involved in the formation of ROS. ROS are formed when iron (Fe2+) 
reacts with H2O2 to form 
•OH (hydroxyl radicals), which are very unstable and reactive, 
via the Fenton reaction (Eq. 1 and 2; Koschnick & Haller, 2006), initiating the processes 
of OS and the inflammatory cascade, that result in the production of cytotoxic 
cytokines in the microglia and surrounding neurons and activation of transcription 
factors (Rival et al., 2001; El & Karakaya, 2004; Weinreb et al., 2009):     
 
O2
- + Fe3+ = O2 + Fe
2+  
H2O2 + Fe
2+ = •OH + OH- + Fe3+ 
(Equation 1) 
(Equation 2) 
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1.1.5.2. Copper and AD 
Copper is an essential component of several enzymes and proteins and is 
critical for numerous reactions vital for life, as for example, antioxidant defense, 
neuropeptide synthesis and immune function (Brewer et al., 2006; Brewer, 2007). The 
deficiency on this element leads to anemia and bone marrow suppression, followed by 
a neurologic syndrome called a myelopathy (Hedera et al., 2003).  
However, like iron, copper also participates in the generation of ROS through 
Fenton chemistry and can produce oxidative damage in much the same manner 
(Brewer et al., 2007).  
At this time the evidences are conflicting whether too much copper is involved 
in the pathogenesis of AD as well as others neurodegeneratives diseases. Some 
authors claim that copper is directly related with the onset of neurological diseases 
(Sayre et al., 2000; Cherny et al., 2001; Nakano et al., 2004; Angeletti et al., 2005; 
Nelson & Alkon, 2005; Soragni et al., 2008; Kong et al., 2008). However, some authors 
such as Phinney et al. (2003) and Bayer et al. (2003) reports in vivo studies where 
amplification of a copper transporter improved brain copper and reduced β-amyloid 
formation, increasing longevity. 
 
1.1.6. Treatment  
 
The pharmacological treatments currently used to alleviate AD symptoms 
include antioxidant therapy, the use of ChE inhibitors, nicotinic and muscarinic 
agonists, estrogen, nerve growth factor (NGF), low molecular lipophilic compounds 
that can activate neurotrophic factor signaling pathway, nonsteroidal antiinflammatory 
drugs such as ibuprofen and COX-2 inhibitors, drugs that interfere with β-amilose 
formation and deposition, and also drugs that attenuate toxicity induced by β-amilose 
(Park & Kim, 2002).    
The changes in the brain of AD patients may begin near 10 years before 
patients experience symptoms such as memory loss, and this is considered as the ideal 
period in which the future drugs should be administered (Jalbert et al., 2008).  
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  1.1.6.1. ChE inhibitors 
Scientists argue that the inhibition of AChE and BChE represents an effective 
therapy for AD management (Grossberg, 2003; Darreh-Shori & Soininen, 2010).  
However, and despite the high demand for ChE inhibitors for AD and other 
neurological disorders, only synthetic AChE inhibitors, such as tacrine and donepezil, 
and the natural products rivastigmine and most recently galanthamine have been 
approved by FDA (Zarotsky et al., 2003).  The latter have been also approved in Europe 
by the European Registration Bureau and is commercially available as Reminyl® (Fig. 
1.6c) (Zarotsky et al., 2003).       
Studies have also revealed the relevance of BChE due to its presence in some 
cholinergic neurons in which AChE is absent, as well as its capability to induce 
neurotoxicity of some plaques (Greig et al, 2005; Oboh et al., 2015). But only 
rivastigmine can inhibit both AChE and BChE (Colovic et al., 2013; Pohanka 2014).   
The above mentioned drugs exhibit some side effects, as for example, 
hepatotoxicity, gastrointestinal disorder, anxiety, nervousness, drowsiness, mouth 
dryness or tiredness and also bioavailability problems, making necessary to find 
alternative ChE inhibitors from natural sources (Pangestuti and Kim 2011). As 
examples, Ginkgo biloba (Ginkgoaceae) and Huperzia serrata (Pteridophyta) have been 
extensively investigated as natural therapeutic agents for AD patients (Park & Kim, 
2002; Conforti et al., 2009). 
 
Galanthamine hydrobromide is a tertiary alkaloid (Fig. 1.6b) that was originally 
isolated from the Galanthus worownii (snowdrop plant) (Fig. 1.6a) (Willis et al., 2009) 
and is now synthesized for use in the treatment of mild to moderate AD (Zarotsky et 
al., 2003; Butler, 2005).  
 
Prior to its use in patients with AD, galanthamine was available in Eastern 
Europe as a curare-reversal agent in anesthesia and as a treatment for neurologic 
conditions, such as myasthenia gravis (Zarotsky et al., 2003).  The interest in this 
compound as a potential treatment for AD was generated on the basis of its ability to 
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reach the brain, penetrating the blood barrier and affect cholinergic transmission 
(Zarotsky et al., 2003).  
 
 
Figure 1.6 a) General aspect of Galanthus worownii  
(Source: http://art-nature-garden-passion-bensimon.blogspot.com/);  
b) chemical structure of galanthamine (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-
methoxy-11-methyl-6H-benzofuro[3a,3,2ef][2]benzazepin-6-ol hydrobromide  
(Source: http://dailymed.nlm.nih.gov/dailymed/);  
c) Reminyl®, galanthamine Alzheimer's drug  
(Source: http://www.sciencephoto.com/media/412296/enlarge). 
 
 
1.1.6.2. Metal chelation as a neuroprotective strategy 
Chelation of the metal ions is considered the main strategy to avoid ROS 
generation (Ebrahimzadeh et al., 2008). 
Antioxidant and other supportive therapies can scavenge ROS and can also 
attenuate inflammation pathways, protecting red blood cells against oxidant damage 
(Ferreira et al., 2006; Ebrahimzadeh et al. 2008). 
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Iron chelators are used to form soluble and stable complexes with iron, which 
are then excreted in the feces and/or urine (Ebrahimzadeh et al., 2008). This iron 
chelation may result in the improvement of life quality and overall survival 
(Ebrahimzadeh et al., 2008).   
Tirosh et al. (2007) reported that the antibiotic iron chelator Clioquinol and the 
continued intramuscular administration of the drug DFO (desferrioxamine) could 
prevent neurotoxicity in mice and slow the clinical progression of AD. However, 
Clioquinol is highly toxic and DFO is poorly passed through the blood–brain barrier 
(Tirosh et al., 2007).   
 
In this sense, special interest has been assigned in nutritional antioxidants and 
metal chelation agents as viable neuroprotective alternative approaches for 
neurodegenerative disorders (Tirosh et al., 2007; Weinreb et al., 2009). These may 
have compounds that can chelate metal ions, such as iron and copper to form inactive 
complexes and prevent the generation of potentially damaging free radicals (Weinreb 
et al., 2009).  
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1.2. Marine Natural Resources   
 
The oceans contain about 90% of the world’s living biomass, which represents 
approximately half of the total global biodiversity (Pangestuti & Kim, 2013). This wide 
diversity of organisms is recognized as an important reservoir of potent and innovative 
molecules responsible for helping them to survive in the hostile environment 
characterized by a competition for space, maintenance of unfouled surfaces, 
deterrence of predation and the ability to successfully reproduce and exhibiting strong 
pharmacological potential (Salvador et al., 2007).  
Among marine organisms, marine algae found attached to rocks in the 
intertidal zone and washed up on the beach in giant underwater forests (Fig. 1.7) have 
been identified as an under-exploited resource for bioactive molecules (Natarajan et 
al., 2009; Pangestuti & Kim, 2011).   
 
 
Figure 1.7 Kelp forest at Catalina Island, California, USA 
(Source: http://www.uwphotographyguide.com/giant-kelp-forests). 
 
Marine algae has been used in traditional medicine in China (Folmer et al., 
2010) and as a subsidiary food (Natarajan et al., 2009) for more than 2000 years. 
Marine algae has also been widely used in Ancient Egyptian and Ayurvedic medicine 
(Folmer et al., 2010). Specifically, Hamed et al., (2015) postulates that the low 
incidence of neurodegenerative diseases in East Asia can be related to their high fish 
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and marine algae consumption. However, there is not enough data currently from 
clinical trials (Cole et al., 2009).  
In Western medicine, the first record of the medicinal use of algae dates back 
to the 1960’s in Italy, in the treatment of breast cancer (Folmer et al., 2010). 
In contrast to seagrasses, that have a true root system (Fig. 1.8b), seeds and 
fruit and veins that carry molecules around the plant, algae have holdfasts and spores 
(Fig. 1.8a) (Coles et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Spores from brown macroalgae Haplospora globosa (a) (Source: 
www.algaebase.org); root system of the seagrass Cymodocea nodosa (b) (Source: 
www.terra.es). 
 
 
Besides their use as antifouling, stabilizers, gelling agents or emulsifiers in food 
industries, a wide number of seaweeds species exhibit important biomedical 
applications, such as the treatment of tuberculosis, arthritis, cold, influenza, worm 
infestations, as a cholesterol lowering drug, ovarian cysts, breast lumps, lymph node 
swellings and lymphomas (Natarajan et al., 2009), antibacterial, antifungal, antiviral 
and/or antitumor (Moreau et al., 2006; Kong et al., 2008; Folmer et al., 2010; Vo & 
Kim, 2010), anticoagulant (Athukorala et al., 2007), antioxidant (Rupérez et al., 2002; El 
& Karakaya, 2004; Lim et al., 2006; Ganesan et al., 2007), anti-allergic (Li et al., 2008), 
anti-inflammatory (Kim et al., 2009) or anti-obesity (Maeda et al., 2007; Tsukui et al., 
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2007; Kong et al., 2010). Apart from all these capabilities, algae can have also interest 
as neuroprotectants (Natarajan et al., 2009).  
 
1.2.1. Macroalgae  
 
Macroalgae can be classified into three classes based on their pigmentation, 
namely brown, red and green algae, which are referred to as Ochrophyta, Rhodophyta, 
and Chlorophyta, respectively (Khan et al., 2010).  
 
Brown macroalgae can contain polysaccharides and diterpenoids (Moreau et 
al., 2006). These diterpenoids display antitumor effects and may include cyclic 
diterpenes from Dictyotaceae species (Gedaraa et al., 2003) or meroditerpenes from 
Cystoseira usneoides (Moreau et al., 2006; Zubia et al., 2009; Taskin et al., 2010) and 
Sargassum tortile (Moreau et al., 2006). In addition, a linear diterpene, 12-(R)-
hydroxygeranylgeraniol, isolated from Bifurcaria bifurcata (Culioli et al., 2004) has 
been reported for its cytotoxicity against cultured human tumor cell lines (Moreau et 
al., 2006).  
Macroalgae polysaccharides has been widely used in the food industry and in 
medicine (Zvyagintseva et al., 1999) and since the 1940s, its production has attained 
commercial significance through their application as thickening and gelling agents for 
several industrial applications (Burtin et al., 2003). 
The main polysaccharides of brown macroalgae are fucoidans, laminarans, and 
alginic acids. In particular, fucoidans and laminarans contents vary from 20 to 50% of 
defatted alga dry weight (Zvyagintseva et al., 1999).  
Fucoidans are nontoxic polyelectrolytes and possess various pharmacological 
activities, as for example, antioxidant, antibacterial, antiviral, antitumor, 
immunosuppressive, antipeptic, antilipemic, antigemostatic and anticoagulant 
(Zvyagintseva et al., 1999). On the other hand, alginic acids can be used for heavy 
metal binding and as immunostimulators (Zvyagintseva et al., 1999; Chandini et al., 
2007; Ye et al., 2008; Koz et al., 2009; Zubia et al., 2009; Chiheb et al., 2009).   
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Macroalgae and its biocompounds can, thus, exhibit numerous remarkable 
properties on biological systems, namely antioxidant (Sathya et al. 2013), anti-
inflammatory (Sugiura et al., 2013), anti-allergic (Sugiura et al., 2009), antimicrobial 
(Eom et al., 2012), anticancer (Lee et al., 2012), antidiabetic (Lee & Jeon, 2013) and 
neuroprotective activities (Barbosa et al., 2014). 
 
1.2.2. Microalgae 
 
Microalgae are constituted by a vast array of novel compounds, such as: 
nutrients (including proteins, vitamins, minerals, fatty acids); carotenoid pigments, 
such as xanthophylls and carotenes; as well as phenolic acids and tocopherols which 
are known to exhibit antioxidant properties (Cha et al., 2008; Raposo et al., 2013). 
Thus, because of the presence of several primary and secondary metabolites in algal 
cells, microalgal biotechnology has received much interest, with its application in the 
energy, food, pharmaceutical and cosmetic industries (Olasehinde et al., 2017). 
Recently, microalgal biotechnology has proved that it is now possible to 
produce some carotenoids commercially through aquaculture (Cha et al., 2008). These 
include, for instance, β-carotene from Dunaliella, astaxanthin from Haematococcus, 
and lutein from Chlorophycean strains (Cha et al., 2008).  Carotenoids are highly 
bioactive and are reported as potent free radical quenchers, singlet oxygen 
scavengers, and lipid antioxidants, thereby acting as photoprotectants under 
conditions of excessive light (Cha et al., 2008). Some carotenoids such as β-carotene 
and lycopene may reduce the risk of cardiovascular diseases and certain cancers, 
whereas lutein and zeaxanthin may reduce the risk of eye disorders (Cha et al., 2008). 
Other carotenoid, such as xanthophylls, extracted from Chlorella ellipsoidea, might be 
also useful as functional ingredients in the prevention of human cancers, since studies 
have shown that these species have antiproliferative effects, including induction of 
apoptosis in vitro cellular models (Cha et al., 2008; Gardeva et al., 2009). Astaxanthin, 
another carotenoid, produced by the microalga Haematococcus pluvialis, has several 
applications in nutraceuticals, cosmetics, food and feed industries and exhibits many 
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essential biological functions, including antioxidant activity and protection against 
lipid-membrane peroxidation of essential polyunsaturated fatty acids and proteins, 
DNA damage, and ultraviolet light effects (Cerón et al., 2007). Studies have also shown 
that they may act through other mechanisms such as gap junction communication, cell 
growth regulation and modulation of gene expression (Cerón et al., 2007; Cha et al., 
2008).   
Cosmetics and nutraceuticals industries may also benefit from the use of 
microalgae biomass as a low cost renewable source of phytosterols and metal 
chelators compounds, due to its high unsaponifiable content (Gangadhar et al., 2016). 
There is also a growing interest in polyunsaturated fatty acids (PUFAs), due to 
their involvement in human health (Alonso et al., 1998; Barreira et al., 2015). 
Microalgae are potential sources of these long-chain PUFAs, especially for 
Eicosapentaenoic acid (EPA, 5,8,11,14,17-cis-eicosapentaenoic acid), which have 
beneficial effects in the prevention and treatment of certain medical conditions 
including coronary heart disease, blood platelet aggregation and several carcinomas 
(Belarbi et al., 2000).   
Oher reports have also revealed the anti-inflammatory (Guzman et al., 2001), 
hypocholesterolemic (Dvir et al., 2015) and antiviral (Huleihel et al., 2002) activities of 
microalgal-derived extracts and compounds. 
Another developing area in the use of microalgae is biodiesel production 
(Chisti, 2007; Damiani et al., 2010; Pereira et al., 2013a, 2013b) (Fig. 1.9), since they 
have a fast growth rate and high photosynthesis efficiency, allowing them to be 
industrially cultivated (Lu et al., 2009). However, since rapid-growing cells contain less 
oil, biodiesel production from microalgae is not economically feasible yet (Lu et al., 
2009). To overcome these biological and technical challenges, Lu et al. (2009) did an 
approach to biodiesel production by a heterotrophic fermentation process with C. 
protothecoides, which produces maximum amounts of algal biomass rich in oil, mainly 
composed by more than 90% of fatty acids (Lu et al., 2009).  
Pereira et al. (2015), for instance, not only proved that microalgae can be a rich 
source of fatty acids, but also showed that microalgae contain molecules with relevant 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 21 
bioactivities, including antioxidant, inhibition of BChE and tyrosines, cytotoxic and 
antileishmanial activities.    
 
 
 
 
Figure 1.9 Biodiesel production by microalgae – closed system bioreactor. Source: 
http://www.global-greenhouse-warming.com/biodiesel-from-algae.html). 
 
 
1.2.3. Seagrasses 
 
Seagrasses are a group of flowering plants (angiosperms) with roots, leaves and 
rhizomes (Coles et al., 2004). They are the only flowering plants that can live 
underwater and are less primitive than algae, whereby there are only about 60 species 
of seagrasses around the world (Coles et al., 2004).   
 
Seagrasses occur in protected bays and lagoons and also in deeper waters and 
the depth at them occurs is limited by water clarity, since most species require high 
levels of light (Coles et al., 2004).  
Although less exploited than algae, seagrasses also contain new commercially 
valuable phytochemicals (Achamlale et al., 2009). Some of them are used as human 
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food or as raw material for the production of compounds with nutritional interest in 
Russia (Achamlale et al., 2009). For example, Achamlale et al. (2009) showed that a 
bioactive pectin from the genus Zostera, zosterin, can decrease the toxicity of 
antitumour drugs and eliminate heavy metals from human organisms.  
Others seagrasses such as Cymodocea nodosa, used in this work, has an 
important ecological role in the marine ecosystem, despite that, knowledge of its 
chemical content is limited (Kontiza et al., 2008).   
 
It has also been described other properties of seagrasses, such as 
antidepressant activity in humans, due especially to the biologically active compounds, 
the cyclitols (Kumar et al., 2008; Nuissier et al., 2008) and antiviral, including HIV-1, 
antioxidant, anti-inflammatory, anticarcinogenic, anti-allergenic and antithrombotic, 
due to the presence of rosmarinic acid (Achamlale et al., 2009; Custódio et al., 2016).  
According to Kumar et al. (2008) the use of the roots of the seagrass Enhalus 
acoroides as a remedy against stings of different kinds of rays and scorpion is very 
popular in India; Cymodocea spp. is used as a tranquillizer for babies, as soothing help 
during pregnancy and against cough and malaria; Halophila spp. is a strong medicine 
against malaria and skin diseases and found to be very effective in early stages of 
leprosy. 
 
1.2.4. Halophytes 
 
Although halophytes represent a small fraction of the overall plant population 
(aprox. 2%), they display important roles in the environment, such as desalinization 
and prevention of soil erosion, loss of biodiversity and bioproductivity (Gago et al., 
2011). These plants can survive in different environments, such as salt marshes and 
estuaries, cliffs and dunes near the ocean, and some are adapted for near-desert 
environments where water supplies may be limited and highly saline (Gago et al., 
2011).  
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Halophytes are considered as good sources of food, fibre and bioenergy (Gago 
et al., 2011). Some halophytes, such as Salicornia ssp., Aster tripolium, Atriplex ssp. or 
Inula crithmoides are consumed in Europe as fresh or cooked gourmet foods, for 
example, in salads as a substitute of salt (Gago et al., 2011; Ventura et al., 2011). They 
have a high nutritional content, which includes proteins, carbohydrates, fiber, calcium, 
potassium, magnesium, iron, manganese, copper, vitamin C and β-carotene (Gago et 
al., 2011).  
It has been reported some important therapeutic applications of different 
halophyte species, as for example, Salicornia spp., including immunomodulation, 
antioxidant and antitumor proporties (Chung et al., 2005).   
Recently, Medini et al. (2015) suggested the strong potential of the halophyte 
Limonium densiflorum as a source of phenolic compounds, marked as having great 
potencial in the food and pharmaceutical industry. In turn, Arthrocnemum 
macrostachyum is rich in phenolics and flavonoids and is also a potential source of 
antioxidants (Custódio et al., 2012 (a); Rodrigues et al., 2014). These secondary 
metabolites play different roles in the physiology and cellular mechanisms of plants, 
including pigmentation as well as resistance to pests, predators and oxidative stress 
(Barreira et al., 2017). The stress conditions to which the halophytes are exposed (high 
salinities and UV radiation), usually trigger to a production of ROS and hence often 
have antioxidant capacity, attributed to their phenolic compounds (Barreira et al., 
2017; Ksouri et al., 2008). This is the case of H. italicum subsp. picardii flowers, with 
similar or even higher antioxidant potential than the commercial green and herbal red 
teas, which has also showed moderate anti-diabetic potential and low toxicity in in 
vitro models (Pereira et al., 2017a). In another study, Pereira et al. (2017b) also tested 
the leaves and the flowers infusions of the halophyte species Crithmum maritimum L. 
and observed its high antioxidant potencial.  
Regarding to ChE inhibitors, Rodrigues et al. (2017) has identified a bioactive 
compound from Juncus acutus, junconol, and proved its capacity to inhibit the enzyme 
AChE on neuronal and glial cells in vitro. 
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1.3. Objective 
 
The number of older people at risk of developing dementia is growing rapidly 
worldwide, and AD represents the most common cause of dementia in the elderly 
(Olasehinde, 2017).  
The search for novel anticholinesterases compounds from natural resources as 
therapeutics agents for AD and other CNS disorders is based on the need for agents 
targeted to brain areas affected, with reduced toxicity and side-effects. 
Marine natural products are considered as important sources of novel 
biologically active compounds, but its application in the treatment of neurological 
disorders is still rather unexplored. In this context, the objective of this study was to 
screen for the AChE and BChE inhibitory activity of some commonly available macro- 
and microalgae, seagrasses and halophytes species of the southern coast of Algarve 
(Portugal), as well as evaluate their chelating activity on iron and copper ions.  
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2. MATERIALS AND 
METHODS 
In this chapter it is described the processes used in the evaluation of the algae, 
seagrasses and halophytes, as potential new sources of bioactive compounds with 
neuroprotective activity. 
 
2.1. Plant material       2.2. Extraction         
2.3. Metal chelating activity 2.4. AChE and BChE inhibitory activity   
2.5. Statistical analysis 
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2.1. Plant material  
 
The list of the species included in this work is presented in Table 2.1. 
Macroalgae (Fig. 2.1) and seagrasses (Fig. 2.2) samples were collected on the 
Algarve coast in July-November 2009. Species identification was made by Dr. Aschwin 
Engelen (Centre of Marine Sciences, University of Algarve, Portugal). Samples were 
washed in seawater, kept cold until arrival to the laboratory, washed with tap water, 
freeze dried, ground with a coffee grinder and stored at -20°C.    
Microalgae (Fig. 2.3) samples were provided by NECTON S.A. as a solid dark 
green frozen paste and were stored at -20°C.  
The halophytes samples were collected in the Ria Formosa lagoon (Fig. 2.4), in 
July-August 2010, which is an area that extends 60 km along the southern coast of 
Portugal (Algarve), covering approximately 18,400 hectares (Gago et al., 2011). Aerial 
parts were washed with tap water, dried at 40°C for 48h, ground with a coffee grinder 
and stored at room temperature. The taxonomical classification was performed by the 
botanist Dr. Manuel J. Pinto (National Museum of Natural History, University of Lisbon, 
Botanical Garden, Portugal).      
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Table 2.1. List of the species included in this work. 
Macroalgae 
Brown Red Green 
Cladostephus spongiosus Asparagopsis armata Chaetomorpha sp. 
Cystoseira compressa Cladophora albida Codium fragile  
C. humilis Jania sp. Codium sp. 
C. nodicalis Peyssonnelia sp. Enteromorpha sp.   
C. tamariscifolia Plocamium cartilagineum Ulva sp. 
C. usneoides Pterocladiella capillacea 
 Dictyota dichotoma 
  D. spiralis 
  Halopteris scoparia  
  Sargassum vulgare 
  Taonia atomaria 
  
   
   
   Microalgae Seagrasses Halophytes 
   Botryococcus braunii Cymodocea nodosa  Arthrocnemum macrostachyum 
Chlorella minutissima Zostera noltei Carpobrotus edulis 
Isochrysis galbana T-ISO 
 
Frankenia hevipes 
Neochloris oleoabundans 
 
Mesebriantemum cristalinum 
Scenedesmus sp. 
 
Salicornia ramosissima 
  
Salsola vermiculata 
  
Sarcocornia fruticosa 
  
Spartina maritima 
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Figure 2.1 General aspects of some macroalgae species included in this work. 
Cystoseira tamariscifolia (a) (brown), Plocamium cartilagineum (b) (red) and Codium 
fragile (c) (green). Source: www.algaebase.org  
 
 
Figure 2.2 General aspect of the seagrasses included in this work. Zostera noltei (a) and 
Cymodocea nodosa (b) (Source: Borum et al., 2004). 
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Figure 2.3 General aspects of some microalgae species included in this work. 
Botryococcus braunii (a) (Source: www.algaebase.org) and Isochrysis galbana (b) 
(Source: www.sciencephoto.com) 
 
Figure 2.4 Ria Formosa lagoon, Algarve (a) (Source: http://algarvecom.blogspot.com) 
and some species of the halophytes species included in this work: Salicornia 
ramossisima (b) (Source: http://www.flickr.com), Sarcocornia fruticosa (c) (Source: 
http://plantas-e-pessoas.blogspot.com), Spartina maritima (d) (Source: 
http://portal.icnb.pt), Salsola vermiculata (e) (Source: http://www.flickr.com) and 
Carpobrotus edulis (f) (Source: http://o-blog-verde.blogs.sapo.pt).   
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2.2. Extraction 
 
Aliquots (1 g) of milled samples were mixed with 20 mL of methanol and 
homogenized in an Ultra Turrax T25 (IKA Labortechnik Basic) in order to disrupt cells 
(1900 rpm in two cycles of 1 minute each). Then, the volume was made up to 40 mL 
with methanol, and samples were extracted for 16h at room temperature (RT, 
approximately 20oC) with stirring.  
 
The extracts were then centrifuged (3000 rpm, 15 min, 20°C, BECKMAN 
COULTER ALLEGRA 6R CENTRIFUGE), the upper layer carefully removed, filtered with 
Whatmann nº 4 filters and dried in a vacuum evaporator (temperature below 50°C, 
ROTAVAPOR R-114). Dried extracts were weight, resuspended in methanol at the 
concentration of 10mg/mL and stored at -20°C. Each extraction was repeated 3 times.  
 
 
2.3. Metal chelating activity 
 
The Fe2+-chelating activity was determined by measuring the formation of the 
Fe2+-ferrozine complex according to Custódio et al. (2012, b). 
Ferrozine can quantitatively form complexes with Fe2+. However, in the 
presence of chelating agents, the complex formation is disrupted with the result that 
the purple colour of the complex is decreased. Measurement of colour reduction, 
therefore, allows for the estimation of the chelating activity of the coexisting chelator 
(Ebrahimzadeh et al. 2008). 
In 96-well microplates, 30 µL of the extracts were added to 200 µL of distilled 
water and then immediately mixed with 30 µL of FeCl2 (0.1 mg/ml water).  
After 30 minutes, 12.5 µL of ferrozine solution (40 mM in water) was added.  
Samples were then incubated at RT for 10 min. and the absorbance was 
measured in a microplate reader (BioTek Synergy 4) at 562 nm.    
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The Cu2+-chelating activity was determined using pirocatechol violet (PV – 
indicator for metal titration) according to Saiga et al. (2003) and Megías et al. (2009). 
In 96-well microplates, 30 µL of the extracts were mixed with 200 µL of Na 
acetate buffer (50 mM, pH 6), 100 µL of CuSO45H2O (5×10
-5 g/mL) and 6 µL of PV (4 
mM in Na acetate buffer).     
The complex of PV with CuSO4 is blue and the colour changes to yellow when 
PV dissociates from Cu2+ ion in the presence of chelating agents. The absorbance was 
measured in a microplate reader (BioTek Synergy 4) at 632 nm. 
Due to the color of the extracts, it was necessary to use a colour control, which 
absorbance was subtracted to the absorbance of the samples, thus only the values 
related to the complex ferrozine-Fe2+ or to the complex PV-CuSO4, in iron and copper 
chelating activity, respectively. In the first case, the sample was added to 242.5 µL of 
distilled water, which volume is the same comprised by the distilled water, FeCl2 and 
ferrozine. In the second case, the sample was added to 306 µL of buffer, which volume 
is the same comprised by buffer, CuSO45H2O and PV.  
 
The extracts were evaluated at the concentrations of 1, 5 and 10 mg/mL and 
results were expressed as percentage of chelating activity relative to a negative control 
containing methanol in place of the sample. A solution of the synthetic metal chelator 
ethylenediaminetetraacetic acid (EDTA) at the concentration of 1 mg/mL was used as 
positive control.  
 
The percentage of chelating activity of Fe2+ and Cu2+ was determined by using 
the next formula: 
 
                                     
                 
        
      
 
Where Acontrol is the absorbance of the negative control and Asample is the 
absorbance of the sample, which was obtained by subtracting the absorbance of the 
colour control.  
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2.4. AChE and BChE inhibitory activity 
 
The AChE and BChE inhibitory activities were assessed by the Ellman’s 
colorimetric assay (Ellman et al., 1961), according to previously described methods 
(Orhan et al. 2006, 2009; Custódio et al., 2012 (b)). 
Briefly, 140 µL of 0.1 mM sodium phosphate buffer (pH 8.0), 20 µL of the 
extracts at the concentrations of 1, 5 and 10 mg/mL and 20 µL of AChE or BChE (0.28 
U/mL) solution were mixed in 96-well microplates and incubated at RT for 15 min. 
Then, 10 µL of the substract acetylthiocholine iodide (AChI) or butyrithiocoline iodide 
(BChI) (4 mg/mL) were added to initiate the reaction, together with 20 µL of a solution 
of the dye 5,5-Dithio-bis (2-nitrobenzoic) acid (DTNB) at the concentration of 1.2 
mg/mL. 
The hydrolysis of AChI and BChI was monitored by the formation of the yellow 
5-thio-2-nitrobenzoato anion as a result of the reaction of DTNB with thiocholines, 
catalyzed by enzymes at a wavelength of 412 nm using 96-well microplate reader 
(BioTek Synergy 4).     
 
Results were expressed as percentage of inhibitory activity relative to a 
negative control containing methanol in place of the sample. Galanthamine was used 
as reference at the concentration of 1 mg/mL.  
The percentage of inhibition of AChE and BChE was determined by using the 
formula: 
 
                                      
                 
        
      
 
Where Acontrol is the absorbance of the negative control and Asample is the 
absorbance of the samples obtained by subtracting the absorbance of the colour 
control.  
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2.5. Statistical analysis 
 
 
All the experiments were carried at least in triplicate and the results were 
expressed as mean ± standard deview (SD).  
One-way analysis of variance (ANOVA) was used to compare the mean values 
of each method, using STATISTICA for Windows (release 7, STATISTICA INC). 
A significant difference between the means of parameters was determined by 
using Kruskal-Wallis multiple comparison tests. A p-value of less than 0.05 was 
considered significant.   
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3. RESULTS 
 
This chapter is divided in two sections, one for the analysis of chelating activity on 
iron and copper and other for the analysis of inhibitory activity on AChE and BChE. 
 
3.1. Iron and copper chelating activity  3.2. ChE inhibitory activity 
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3.1. Iron and copper chelating activity  
 
In this work we applied the classification suggested by Vinutha et al. (2007) for 
the AChE inhibitory activity to the metal chelating activity, to make easier the 
interpretation of the results. In this sense, metal chelating activity was classified as: 
potent (>50% activity), moderate (30–50% activity), low (<30% activity) or nil (<5% 
activity).    
 
 3.1.1. Fe2+ chelating activity 
 
In the used method, the higher the chelation of ions by the sample, the smaller 
the number of ions available for reaction with ferrozine, so the reaction does not get 
the purple colour characteristic of the complex Fe2+-ferrozine. Thus, the lower the 
absorbance of the reaction mixture, the higher the Fe2+-chelating ability (Fig. 3.1).  
 
Figure 3.1 Example of 96-well microplates with an iron chelating assay employing 
methanol extracts with low Fe2+ chelating activity. The concentrations of the extracts 
are increasing from top to bottom. The darker the reaction, the lower the chelating 
activity of the tested extract.   
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3.1.1.1. Macroalgae 
 
The chelating activity varied between groups of macroalgae and significant 
differences were found between them (Fig. 3.2).  
The best results were obtained in the group of red macroalgae, followed by the 
brown macroalgae and for last, the green macroalgae, where no relevant activities 
were detected (Fig. 3.2).   
 
Regarding brown macroalgae, the species D. dichotoma displayed the highest 
iron chelating potential, with a value of 52.7% at 10 mg/mL (Fig. 3.2). The species P. 
cartilagineum (red) also had a potent chelating activity (83.4% at 10 mg/mL), while for 
the group of green macroalgae, the maximum value was obtained with the species 
Enteromorpha sp (30.5%; Fig. 3.2) at the highest concentration tested.     
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Figure 3.2 Fe2+ chelating activity (%) of methanol extracts of brown (A), red (B) and green (C) macroalgae species. For the same group 
(brown, red or green), bars labelled with different letters are significantly different at p<0.05 (Kruskal-Wallis multiple comparison test). 
 
 
 
 
Brown macroalgae
C.
 sp
on
gio
su
s
C.
 co
mp
res
sa
C.
 hu
mi
lis
C.
 no
dic
au
lis
C.
 ta
ma
ras
cif
oli
a
C.
 us
ne
oid
es
D.
 di
ch
oto
ma
D.
 sp
ira
lis
H.
 sc
op
ari
a 
S. 
vu
lga
re
T. 
ato
ma
ria
Fe
2
+  
ch
el
at
in
g 
ac
ti
vi
ty
 (
%
)
0
20
40
60
80
100
Red macroalgae
A. 
arm
ata
C.
 al
bid
a
Ja
nia
 sp
.
Pe
ys
so
nn
eli
a s
p
P. 
ca
rtil
ag
ine
um
P. 
ca
pil
lac
ea
Green macroalgae
Ch
ae
tom
orp
ha
 sp
.
C.
 fra
gil
e 
Co
diu
m 
sp
En
ter
om
orp
ha
 sp
.
Ulv
a s
p.
1 mg/ml
5 mg/ml
10 mg/ml
A B C
Fe
2
+ ch
elatin
g activity (%
)b
a bc a cc
a
a
a abc ab
a
cc
b
ab
bc
b
ab
bc
bc
a
b
b bc
b
b b
a
a
a
b
b
ab
ab
ab
ab
b
b
b
b
aa
a
a a
b
b
b
bc
bc
bcbc bc
c
ab
ab
bc bc
bc
b
b
b
b
bc
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 38 
 
3.1.1.2. Microalgae 
 
The species I. galbana was the most active followed by B. braunii with 
maximum values of 64.4% and 59.7% at the concentration of 10 mg/mL, respectively 
(Fig. 3.3).    
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Figure 3.3 Fe2+ chelating activity (%) of methanol extracts of microalgae species. Bars 
labelled with different letters are significantly different at p<0.05 (Kruskal-Wallis 
multiple comparison test).  
 
 
3.1.1.3. Seagrasses 
  
None of the seagrasses tested had relevant capacity to chelate iron (Fig. 3.4).  
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Figure 3.4 Fe2+ chelating activity (%) of methanol extracts of C. nodosa and Z. noltei 
species. Bars labelled with different letters are significantly different at p<0.05 
(Kruskal-Wallis multiple comparison test). 
 
 
 
3.1.1.4. Halophytes 
 
Two species had moderate capacity to chelate iron at 10 mg/mL, namely M. 
cristalinum (35.6%) and S. ramosissima (38%) (Fig. 3.5).   
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Figure 3.5 Fe2+ chelating activity (%) of methanol extracts of halophytes species. Bars 
labelled with different letters are significantly different at p<0.05 (Kruskal-Wallis 
multiple comparison test). 
 
  
3.1.2. Cu2+ chelating activity 
 
In this assay, it is observed a decrease in the characteristic blue colour of the 
complex Cu2+-PV to a yellowish colour with the increase of the chelating activity of the 
tested sample (Fig. 3.6).   
In general, the extracts had the capacity to chelate Cu2+, and this activity was 
concentration dependent, increasing with increasing concentrations of the extracts 
(Fig. 3.6).   
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Figure 3.6 General aspect of a copper chelation assay made in 96-well microplates. 
Plate A) negative control (C-); positive control (C+); methanol extracts of the green 
macroalgae C. fragile at the concentrations of 1 (CF1), 5 (CF5) and 10 (CF10) mg/mL; 
methanol extracts of the halophyte F. laevis  at the concentrations of 1 (FH1), 5 (FH5) 
and 10 (FH10) mg/mL. Plate B) colour controls made to the assays using the species in 
plate A.  
 
 
  3.1.2.1. Macroalgae 
 
The copper chelating activity was significantly higher in brown and red 
macroalgae extracts (Fig. 3.7). 
Regarding brown algae, the best result was obtained with the species H. 
scoparia (64.0%) at the concentration of 10 mg/mL (Fig. 3.7).  Three of the red 
macroalgae tested had potent activities, namely C. albida (62.7%), P. cartilagineum 
(63.9%) and P. capillacea (62.4%) at the concentration of 10 mg/mL (Fig. 3.7). The 
green species Enteromorpha sp. exhibited potent ability to chelate copper ions 
(56.1%), at the concentration of 10 mg/mL (Fig. 3.7).       
Of all the macroalgae tested, the best preventing the formation of the complex 
Cu2+-PV was the brown algae H. scoparia and the red algae P. cartilagineum and P. 
capillacea, with similar activities.  
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 Figure 3.7 Cu2+ chelating activity (%) of methanol extracts of brown (A), red (B) and green (C) macroalgae species. For the same group 
(brown, red or green), bars labelled with different letters are significantly different at p<0.05 (Kruskal-Wallis multiple comparison test). 
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3.1.2.2. Microalgae 
 
Four of the five species tested had more than 40% of Cu2+ chelating capacity 
even at a concentration of 5 mg/mL and in the case of I. galbana and N. Oleoabundans, 
a potent activity was observed at the higher concentration tested, 69,7% and 67,5%, 
respectively (Fig. 3.8).   
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Figure 3.8 Cu2+ chelating activity (%) of methanol extracts of microalgae species. Bars 
labelled with different letters are significantly different at p < 0.05 (Kruskal-Wallis 
multiple comparison test). 
 
 
3.1.2.3. Seagrasses 
 
The species Z. noltei and C. nodosa exhibited potent and moderate capacity to 
chelate Cu2+ ions, with values of 54.8% and 49.3%, respectively, for the highest 
concentration tested (Fig. 3.9). 
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Figure 3.9 Cu2+ chelating activity (%) of methanol extracts of C. nodosa and Z. noltei 
species. Bars labelled with different letters are significantly different at p < 0.05 
(Kruskal-Wallis multiple comparison test). 
 
 
3.1.2.4. Halophytes 
 
Halophytes species displayed the highest values of Cu2+ chelation. In fact, 75% 
of the species had a potent capacity to chelate Cu2+ and the best result was obtained 
with F. laevis with a potent activity even at the lowest concentration tested (1 mg/mL: 
73.9%) (Fig. 3.10). 
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Figure 3.10 Cu2+ chelating activity (%) of methanol extracts of halophytes species. Bars 
labelled with different letters are significantly different at p < 0.05 (Kruskal-Wallis 
multiple comparison test). 
 
 
 
Compared with iron, the chelating activity was higher for copper in the majority 
of the cases.  
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3.2. ChE Inhibitory activity 
 
The inhibitory activity (%) of AChE and BChE was also classified according to 
Vinutha et al. (2007) as potent (>50%), moderate (30-50%), low (<30%) or nil (<5%).   
 
3.2.1. AChE inhibitory activity 
 
The AChE inhibitory activity of the different species is summarized in Fig. 3.11 
for macroalgae, Table 3.1 for microalgae, Table 3.2 for seagrasses and Fig. 3.12 for 
halophytes.  
In general, the group with most potent capacity to inhibit AChE was the group 
of brown macroalgae.  
  
 
3.2.1.1. Macroalgae 
 
The AChE inhibitory activity of the extracts varied significantly among the three 
types of macroalgae tested, being highest in the group of brown macroalgae and 
lowest in the green macroalgae group (Fig. 3.11).    
The brown species C. compressa and C. tamariscifolia had the highest AChE 
inhibition, with high values at the lower concentration tested (1 mg/mL), 71.6% and 
70.8%, respectively (Fig. 3.11).      
In the rodophyta group, only the specie A. armata displayed a potent inhibition 
(58.6%) at the concentration of 10 mg/mL (Fig. 3.11). Generally, all the chlorophyta 
species displayed nil or low AChE inhibitory activity (Fig. 3.11).   
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Figure 3.11 AChE inhibitory activity (%) of methanol extracts of brown (A), red (B) and green (C) macroalgae species. Bars groups labelled 
with different letters are significantly different at p<0.05 (Kruskal-Wallis multiple comparison tests).  
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3.2.1.2. Microalgae 
 
All the species of microalgae tested showed nil or low inhibitory activity against 
AChE (Table 3.1).  
 
Table 3.1. AChE inhibitory activity (%) of methanol extracts of microalgae species.    
 
AChE INHIBITORY ACTIVITY (%) 
Concentration 
Microalgae 
1 mg/mL 5 mg/mL 10 mg/mL 
B. braunii 9.7 ± 1.8a 6.0 ± 1.1a n.a. 
C. minutissima n.a. n.a. n.a. 
I. galbana T-ISO 13.0 ± 2.4a 16.0 ± 2.7a 16.2 ± 3.4a 
N. oleoabundans n.a. n.a. n.a. 
Scenedesmus sp. n.a. n.a. n.a. 
Galanthaminea 90.5 ± 0.6 
                a 
Positive control (1 mg/mL). Data presented as mean ± SD of at least 3 independent experiments.  
        n.a. – No activity. In the same row values labelled with different letters are significantly different at 
p < 0.05 (Kruskal-Wallis multiple comparison test). 
 
 
3.2.1.3. Seagrasses 
 
The species Z. noltei had no inhibitory effect on AChE, while C. nodosa exhibited 
a moderate activity at the concentration of 10 mg/mL (Table 3.2).   
 
Table 3.2. AChE inhibitory activity (%) of methanol extracts of seagrasses species. 
 
AChE INHIBITORY ACTIVITY (%) 
Concentration 
Seagrasses 
1 mg/mL 5 mg/mL 10 mg/mL 
C. nodosa 13.0 ± 1.95c 29.3 ± 2.60b 36.7 ± 1.18a 
Z. noltei n.a. n.a. n.a. 
Galanthaminea 90.5 ± 0.6 
         aPositive control (1 mg/mL). Data presented as mean ± SD of at least 3 independent experiments.  
            n.a. – No activity. In the same row values labelled with different letters are significantly different 
at p < 0.05 (Kruskal-Wallis multiple comparison test). 
 
 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 49 
3.2.1.4. Halophytes 
 
The most bioactive species were C. edulis and F. laevis with potent inhibitory 
activity at the lowest concentration tested, 56.4% and 78.3%, respectively (Fig. 3.12).   
 
With the exception of A. macrostachyum, which showed a moderate activity at 
the concentrations of 5 and 10 mg/mL (Fig. 3.12), all the other species had low or nil 
activities at those concentrations (Fig. 3.12).   
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Figure 3.12 AChE inhibitory activity (%) of methanol extracts of halophytes species. 
Bars labelled with different letters are significantly different at p < 0.05 (Kruskal-Wallis 
multiple comparison test). 
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3.2.2. BChE inhibitory activity 
 
In order to further explore the ChE inhibitory properties of the active extracts, 
those with potent activity (>50%) against AChE were tested on BChE and the results 
are summarized on Fig. 3.13.   
 
The highest inhibitory activity against BChE was achieved with the application 
of the extracts from the Cystoseira genus, in particular the species C. nodicaulis 
(92.2%) and C. tamariscifolia (100%) and also with the halophytes species C. edulis 
(76.8%) and F. laevis (93.2%; Fig. 3.13), all applied at the concentration of 10 mg/mL.  
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Figure 3.13 BChE inhibitory activity (%) of methanol extracts of 4 brown macroalgae, 1 
red macroalgae and 2 halophytes. Bars labelled with different letters are significantly 
different at p < 0.05 (Kruskal-Wallis multiple comparison test). 
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4. DISCUSSION 
 
Here the results are discussed and compared with the literature. 
 
4.1. Iron and copper chelating activity        4.2. AChE and BChE Inhibitory activity 
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4.1. Iron and copper chelating activity  
 
One of the factors that can cause neurodegenerative diseases such as AD, PD 
and Huntington’s disease can be the total iron and copper concentration increasing in 
some brain regions (Brewer, 2010).   
Iron might have a direct impact on plaque formation, due to its action as a 
modulator in α-secretase to cleave APP (Huang et al. 2000; Rodgers et al., 2002; 
Kawahara, 2003; Zecca et al., 2004). In turn, tau protein, a component of 
neurofibrillary tangles, binds copper, required for its aggregation (Soragni et al., 2008).    
Moreover, these transition metals generate free radicals from peroxides via 
Fenton reactions and, therefore, the reduction of their levels can offer protection 
against oxidative damage (Rival et al., 2001).  
 
In this work, the chelating activity was higher for copper than in iron in the 
majority of the cases and the most promising was the species P. cartilagineum (Fig. 
3.2).  
 
There are some studies reporting the iron chelating properties of different 
macroalgae species. The methanolic extracts of the green macroalgae, Ulva rigida, and 
the brown macroalgae, Fucus spiralis, collected from Marocco coastal area, displayed 
interesting iron chelating capacity (Chernane et al., 2014). 
Extracts using chloroform, methanol, petroleum ether and ethyl acetate from 
the red macroalga Asparagopsis taxiformis, collected in the south coastal of India, have 
also displayed relevant values of Fe2+-chelating activity (Neethu et al., 2017).  
In a study by Alencar et al. (2016) a moderate Fe2+-chelating activity was 
observed in ethanol and hexane extracts of the red macroalgae Pterocladiella 
capillacea.  
The green macroalgae Ulva faciata and the red Gracilaria corticata can also 
highly chelate ferrous ions, especially extracts using dichloromethane and ethylacetate 
(Taheri, 2016).  
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There are very few reports of research on microalgae capacity to chelate 
metals. Custódio et al. (2012b) observed that hexane extracts of microalgae species 
namely Tetraselmis chuii, Nannochloropsis oculata, Chlorella minutissima and 
Rhodomonas could chelate Cu2+ ions. In another study, water extract from N. oculata 
also showed a relevant Cu2+- chelating activity (Custódio et al., 2014).  
More recently, Trabelsi et al. (2016) tested the microalgae Graesiella sp. and 
find its elevated potencial on Fe2+-chelating activity.   
  
A few publications were found about the metal chelating capacity of seagrasses 
and halophytes. El & Karakaya (2004), who tested some greens used as traditional 
dishes in Mediterranean diet, including the halophyte Salicornia europaea (methanolic 
extracts) observed that this species had the capacity to chelate iron. Besides, 
methanolic extract of the halophyte Limonium algarvense, also collected in the south 
of Portugal, showed a relevant copper chelating activity (Rodrigues et al., 2015).   
 
All together the results suggests that the species P. cartilagineum and I. 
galbana could be sources of natural products and / or compounds with metal 
chelation potential, and thus, with interest in the management of oxidative stress-
linked neurological diseases. 
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4.2. AChE and BChE Inhibitory activity 
 
There has been some research on the biological effect of plants traditionally 
used either in infusions or in traditional remedies as AChE inhibitors in vitro and also as 
memory enhancers in vivo (Tildesley et al., 2003). These studies are carried out in 
order to find new molecules or a group of molecules that can be used in the AD 
therapy without the toxicity of the synthesized chemical compounds (Ferreira et al., 
2006).  
Marine resources, particularly macroalgae, are a promising source of 
biocompounds with a wide range of bioactivities, including neuroprotective effects 
(Barbosa et al. 2014). Despite this, some authors, as for example, Grosso et al. (2014), 
believe that few of these sources will be successfully marketed, since its consumption 
could jeopardize the marine ecosystem’s sustainability (Barbosa et al. 2014). In order 
to overcome this problem, it is crucial to implement new and greener strategies like 
efficient cultivation techniques (Reddy et al., 2008).  
  
From the results obtained in this work, it is clear that, regarding macroalgae, 
the extracts of the brown algae C. compressa, C. nodicaulis and C. tamariscifolia are 
capable to inhibit both AChE and BChE in vitro. Natural extracts with dual anti-ChE 
activity may be appropriate to patients at a moderate stage of AD, where the level of 
AChE use has not yet significantly declined but where the possibility that BChE could 
hydrolyse ACh exists (Mesulam et al., 2002). In adition, the use of compounds with 
dual ChE inhibition are reported to increase the efficacy of the treatment and expand 
their uses to other disorders from the CNS, as for example Down syndrome and also to 
patients suffering from traumatic brain injuries (Giacobini, 2004). 
In a previous report, Andrade et al. (2013) evaluated the AChE and BCHE 
inhibitory properties of ethanol extracts of different brown, red and green algae. 
Contrary to our results those authors obtained a strong AChE inhibition in extracts 
from C. usneoides and no activity in those of C. tamariscifolia and A. armata. Still in 
that work, a moderate activity against BChE was observed after application of samples 
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from C. tamariscifolia. The differences between our funding and those from other 
authors are most probably due to the different collection sites and / or exctration 
methods.  
 
The high ChE inhibitory capacity of C. tamariscifolia, C. compressa and C. 
nodicaulis, can be related with the presence of phenolic compounds in these species 
(Custódio et al., 2016). Phenolic compounds are one of the most therapeutically useful 
molecules due to their capacity to prevent oxidative stress-mediated disorders, 
including neurodegenerative disorders (Rodríguez-Morató et al., 2015). In algae 
phenolic compounds are related with the defence of the thallus against for example 
UV-induced damage and herbivory (Abdala-Díaz et al., 2006). Cystoseira tamariscifolia, 
one of the most active species, was previously reported to contain high levels of 
hydroxycinnamic acids, which were reported as neuroprotective agents in in vivo 
studies in rats and mice (Cheng et al., 2008; Tsai et al., 2011). 
 
There are other reports on the inhibition of AChE and BChE by different 
extracts of brown macroalgae, such as ethanolic extracts of the species Ecklonia 
stolonifera (Yoon et al., 2008) and chloroform extracts of the Sargassum sagamianum 
(Choi et al., 2007; Natarajan et al., 2009) and from methanolic extracts of the green 
Ulva reticulata (Suganthy et al., 2010). The last species, U. reticulata, exhibited a 
higher inhibitory activity towards AChE and BChE than the anti-AChEs in current clinical 
use, making this seaweed an interesting potential source of compounds for AD 
management (Choi et al., 2007; Natarajan et al., 2009).      
The following macroalgae were also found to be capable to inhibit AChE: Ishige 
okamurae, Dictyota humifusa and Padina gymnospora (brown) and Hypnea valentiae 
and Gracilaria edulis (red) (Stirk et al., 2007; Yoon et al., 2009; Suganthy et al., 2010). 
Moreover, H. valentiae (red), Enteromorpha intestinalis (green) and Dictyota 
dichotoma (brown) displayed a strong BChE inhibitory activity (Suganthy et al., 2010).  
Kannan et al. (2013) have proved that extracts using methanol, hexane, 
dichloromethane, ethyl acetate and butanol of the brown macroalga Ecklonia maxima, 
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from the coast of South Africa, display great AChE inhibitory activity, probably because 
of the phlorotannins, compounds with a large molecular size and a big number of 
hydroxyl groups, which are able to modulate the interaction with AChE and 
consequent inhibition of the enzyme.  
 
In this work no relevant ChE inhibory capacity was detected on extracts from 
microalgae. There are few reports on the AChE inhibitory potential of microalgae 
species. Contrary to our results in a previous work (Custódio et al., 2012 (b)), it was 
observed that an hexane extract from Chlorella minutissima had high capacity to 
inhibit AChE, while ether and water extracts from Scenedesmus spp and I. galbana, and 
ether and hexane extracts from B. braunii were able to inhibit AChE (Custódio et al., 
2014, 2015).  
These differences maybe ascribed to the different extracts tested, that allows 
for the extraction of compounds with different inhibitory capacity against 
cholinesterases (Custódio et al., 2012 (b), 2014, 2015). 
Moreover, it is also known that the composition of bioactive compounds of a 
natural extract obtained from algae varies significantly with the conditions to which 
the organisms are subjected such as algae size, age, tissue type, salinity, season, 
nutrient levels, light intensity and water temperature (Lopes et al., 2012). 
 
The seagrasses included in this work showed no capacity to inhibit AChE or 
BChE. Similar results were obtained with methanol crude extracts and fractions of Z. 
noltei (Custódio et al., 2016).  
 
As for the halophyte species, C. edulis and F. laevis had the highest dual inhition 
against both enzymes. Similar results were previously reported for methanol extracts 
from C. edulis (Custódio et al., 2012 (a); Rocha et al., 2017), and the activity can be 
related with its high phenolic content (Rocha et al., 2017).  
Carpobrotus edulis, usually called sour fig, is a medicinal and edible species 
native to the coast of South Africa. Sour fig has different traditional uses, as for 
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example, for the treatment of diarrhoea, tuberculosis, diabetes mellitus, to treat gum 
infections and burn wounds (Van Wyk, 2008; Van Wyk et al., 1997; Van Der Watt and 
Pretorius, 2001; Thring and Weitz, 2006; Martins et al., 2011; Ksouri et al., 2012; 
Omoruyi et al., 2012). This species was introduced in the southern and western 
Europe, including Portugal, for landscaping and to stabilize coastal sand dunes. 
Nevertheless, it became invasive mainly due to its high successful reproduction and 
dispersal capacity.  
Sour fig is edible and has a nutritional profile adequate for human consumption 
(Rocha et al., 2017). Moreover, it has a high antioxidant potential and exhibits multiple 
in vitro neuroprotective features (Rocha et al., 2017) which suggests that it is a 
potential source of natural products able to improve cognitive functions. 
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5. CONCLUSION AND 
FUTURE PERSPECTIVES 
 
Presentation of the conclusions of this work, according to the most significant results 
obtained and future perspectives. 
 
  
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 59 
 
This study provides data regarding the in vitro metal chelating and 
cholinesterase inhibitory activities of several species of algae, includind macro- and 
micro-, seagrasses and halophytes species.  
The objectives of this thesis have been successfully achieved, since several 
species displayed relevant activities and thus, were identified as interesting potential 
sources of innovative products and /or molecules able to improve cognitive functions 
and, thus, for the management of neurodegenerative diseases.    
 
Specifically, the extracts of the brown macroalgae species C. compressa, C. 
nodicaulis and C. tamariscifolia and from the halophytes C. edulis and F. laevis 
displayed both AChE and BChE inhibitory activities and may be a potential source of 
novel products useful in alleviating the symptoms associated with AD and other 
neurogenerative ailments. Also the red algae P. cartilagineum and the microalgae I. 
galbana may contain strong metal-chelating compounds. Thus, these species are 
promising candidates for more detailed in vitro and in vivo studies.    
 
As for future perspectives, further studies would be needed in order to further 
explore their therapeutic potential, as for example, through the isolation and 
identification of the bioactive compounds present in the extracts; elucidation of the 
mechanisms of actions and by performing in vivo studies using mammalian models of 
neurodegeneration.  
  
 
 
 
 
 
 
 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 60 
 
 
 
 
 
 
 
 
 
 
6. REFERENCES 
 
List of literary references cited. 
  
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 61 
Abdala-Díaz, R.T.; Cabello-Pasini, A.; Pérez-Rodríguez, E.; Álvarez, R.M.C. & Figueroa, 
F.L. (2006). Daily and seasonal variations of optimum quantum yield and phenolic 
compounds in Cystoseira tamariscifolia (Phaeophyta). Marine Biology, , 148–459.  
Achamlale, S.; Rezzonico, B. & Grignon-Dubois, M. (2009). Rosmarinic acid from beach 
waste: Isolation and HPLC quantification in Zostera detritus from Arcachon lagoon. 
Food Chemistry, 113, 878–883. 
Alencar, D.B.; Carvalho, F.; Rebouças, R. et al. (2016). Bioactive extracts of red 
seaweeds Pterocladiella capillacea and Osmundaria obtusiloba (Floridophyceae: 
Rhodophyta) with antioxidant and bacterial agglutination potential. Asian Pacific 
Journal of Tropical Medicine, 9, 372–379.  
Alonso, D.L.; Belarbi, E.; Rodriguez-Ruiz, J.; Segura, C.I. & Giménez, A. (1998). Acyl 
Lipids of Three Microalgae. Phytochemistry, 47, 1473–1481. 
Alzheimer’s Disease International. World Alzheimer’s Report 2015: The Global Impact 
of Dementia, An Analysis of Prevalence, Incidence, Cost and Trends; Alzheimer’s 
Disease International, London, UK, 2015, 5–10. 
Andrade, P.B.; Barbosa, M.; Matos, R.P.; Lopes, G.; Vinholes, J.; Mouga, T. & Valentão, 
P. (2013). Valuable compounds in macroalgae extracts. Food Chemistry, 138, 
1819–1828.  
Angeletti, B.; Waldron, K.J.; Freeman, K.B.; Bawagan, H.; Hussain, I.; Miller, C.C.; Lau, 
K.F.; Tennant, M.E.; Dennison, C.; Robinson, N.J. & Dingwall, C. (2005). BACE1 
cytoplasmic domain interacts with the copper chaperone for superoxide 
dismutase-1 and binds copper. Journal of Biological Chemistry, 280, 17930–17937. 
Athukorala, Y.; Lee, K.; Kim, S. & Jeon, Y. (2007). Anticoagulant activity of marine green 
and brown algae collected from Jeju Island in Korea. Bioresource Technology, 98, 
1711–1716.  
Barbosa, M.; Valentão, P. & Andrade, P.B. (2014). Bioactive Compounds from 
Macroalgae in the New Millennium: Implications for Neurodegenerative Diseases. 
Marine Drugs, 12, 4934-4972 
Barreira, L.; Pereira, H.; Gangadhar, K.N; Custódio, L. & Varela, J. (2015). Medicinal 
Effects of Microalgae-Derived Fatty Acids. Handbook of Marine Microalgae, 
Biotechnology Advances, 1st Ed., Se-Kwon Kim, 209–231. 
Barreiraa, L.; Reseka, E.; Rodrigues, M.J.; Rocha, M.I.; Pereira, H.; Bandarra, N.; Silva, 
M.M.; Varela, J. & Custódio, L. (2017). Halophytes: Gourmet food with nutritional 
health benefits? Journal of Food Composition and Analysis, 59, 35–42. 
Bayer, T.A.; Schafer, S.; Simons, A.; Kemmling, A.; Kamer, T.; Tepest, R. et al. (2003). 
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid 
Abeta production in APP23 transgenic mice. Proceedings of the Association of 
American Physicians, 100, 14187–14192. 
Belarbi, E.; Molina, E. & Chisti, Y. (2000). A process for high yield and scaleable 
recovery of high purity eicosapentaenoic acid esters from microalgae and fish oil. 
Process Biochemistry, 35, 951–969. 
Borum, J.; Duarte, C.M.; Krause-Jensen, D. & Greve, T.M. (2004). European seagrasses: 
an introduction to monitoring and management. Monitoring and Managing of 
European Seagrasses.  
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 62 
Brewer, G.J.; Harris, E.D. & Askari, F.K. (2006). Normal copper metabolism and 
lowering copper to subnormal levels for therapeutic purposes. Textbook of 
Hepatology: From basic science to clinical practice, Benhamou JP, Rizzetto M, 
Reichen J, Rode´s J, Blei A, Eds., Blackwell Publishing, Oxford, England.  
Brewer, G.J. (2007). Iron and Copper Toxicity in Diseases of Aging, Particularly 
Atherosclerosis and Alzheimer’s Disease. Experimental Biology and Medicine, 232, 
323–335. 
Brewer, G.J. (2010). Risks of Copper and Iron Toxicity during Aging in Humans. 
Chemical Research in Toxicology, 23, 319–326 
Burtin, P. (2003). Nutritional Value of Seaweeds. Electronic Journal of Environmental, 
Agricultural and Food Chemistry, 2, 498–503.  
Butler, M. S. (2005). Natural products to drugs: natural product derived compounds in 
clinical trials. Natural Products Reports, 22, 162–195. 
Carter, P. (1971). Spectrophotometric determination of serum iron at the 
submicrogram level with a new reagent (ferrozine). Analytical Biochemistry, 40, 
450–458.   
Cerón, M.C.; García-Malea, M.C.; Rivas, J.; Acien, F.G.; Fernandez, J.M.; Del Río, E.;  
Guerrero, M.G. & Molina, E. (2007). Antioxidant activity of Haematococcus 
pluvialis cells grown in continuous culture as a function of their carotenoid and 
fatty acid content. Applied Microbiology and Biotechnology, 74, 1112–1119. 
Cha, K.H.; Koo, S.Y. & Lee, D. (2008). Antiproliferative Effects of Carotenoids Extracted 
from Chlorella ellipsoidea and Chlorella vulgaris on Human Colon Cancer Cells. 
Journal of Agricultural and Food Chemistry, 56, 10521–10526.   
Chandini, S.K.; Ganesan, P. & Bhaskar, N. (2008). In vitro antioxidant activities of three 
selected brown seaweeds of India. Food Chemistry, 107, 707–713.  
Cheng, C.Y.; Ho, T.Y.; Lee, E.J.; Su, S.Y.; Tang, N.Y. & Hsieh, C.L. (2008). Ferulic acid 
reduces cerebral infarct through its antioxidative and anti-inflammatory effects 
following transient focal cerebral ischemia in rats. The American Journal of Chinese 
Medicine, 36, 1105–1119. 
Chernane, H.; Mansori, M.; Latique, S. & Kaoua, M. E. (2014). Evaluation of antioxidant 
capacity of methanol extract and its solvent fractions obtained from four 
moroccan macro algae species. European Scientific Journal, 10, 35–48.  
Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, W.D.; McLean, C.A. et al. 
(2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-
amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron, 30, 665–
676. 
Chiheb, I.; Riadi, H.; Martinez-Lopez, J.; Dominguez, S.J.; Gomez, V.J.; Bouziane, H. & 
Kadiri, M. (2009). Screening of antibacterial activity in marine green and brown 
macroalgae from the coast of Morocco. African Journal of Biotechnology, 8, 1258–
1262. 
Chisti, Y. (2007). Biodiesel from microalgae. Biotechnology Advances, 25, 294–306. 
Choi, B.W.; Ryu, G.; Park, S.H.; Kim, E.S.; Shin, J.; Roh, S.S. et al. (2007). 
Anticholinesterase activity of plastoquinones from Sargassum sagamianum: Lead 
compounds for Alzheimer’s disease therapy. Phytotherapy Research, 21, 423–442. 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 63 
Chung, Y.C.; Chun, H.K.; Yang, J.Y.; Kim, J.Y.; Han, E.H.; Kho, Y.H. & Jeong, H.G. (2005). 
Tungtungmadic Acid, a Novel Antioxidant, from Saficornia herbacea. Archives of 
Pharmacal Research, 28, 1122–1126.  
Cole, G.M.; Ma, Q.L. & Frautschy, S. A. (2009). Omega-3 fatty acids and dementia. 
Prostaglandins Leukot Essent Fatty Acids, 81, 213–21. 
Coles, R.; McKenzie, L.; Campbell, S.; Mellors, J.; Waycott, M. & Goggin, L. (2004). 
Seagrasses in Queensland Waters. CRC Reef Research Centre. 
Colovic, M. B.; Krstic, D. Z.; Lazarevic-Pašti, T. D.; Bondžic, A. M.; Vasic, V. M. (2013). 
Acetylcholinesterase inhibitors: Pharmacology and toxicology. Current 
Neuropharmacology, 11, 315–335. 
Conforti, F.; Rigano, D.; Menichini, F.; Loizzo, M.R. & Senatore, F. (2009). Protection 
against neurodegenerative diseases of Iris pseudopumila extracts and their 
constituents. Fitoterapia, 80, 62–67. 
Culioli, G.; Ortalo-Magné, A.; Daoudi, M.; Thomas-Guyon, H.; Valls, R. & Piovetti, L. 
(2004). Trihydroxylated linear diterpenes from the brown alga Bifurcaria bifurcata. 
Phytochemistry, 65, 2063–2069. 
Custódio, L.; Ferreira, C.; Pereira, H.; Silvestre, L.; Duarte, C.; Barreira, L.; Rauter, A.P.; 
Alberício, F. & Varela, J. (2012a). The marine halophytes Carpobrotus edulis L. and 
Arthrocnemum macrostachyum L. are a potential source of nutritionally important 
PUFAs and biocompounds with antioxidant, metal chelating and anticholinesterase 
inhibitory activities. Botanica Marina, 55, 281–288. 
Custódio, L.; Justo, T.; Silvestre, L.; Barradas, A.; Duarte, C. V.; Pereira, H.; Barreira, L.; 
Rauter, A. P.; Alberício, F. & Varela, J. (2012b). Microalgae of different phyla 
display antioxidant, metal chelating and acetylcholinesterase inhibitory activities. 
Food Chemistry, 131, 134–140.   
Custódio, L.; Soares, F.; Pereira, H.; Rodrigues, M. J.; Barreira, L.; Rauter, A.P.; Alberício, 
F. & Varela, J. (2014). Fatty acid composition and biological activities of Isochrysis 
galbana T-ISO, Tetraselmis sp. and Scenedesmus sp.: possible application in the 
pharmaceutical and functional food industries. Journal of Applied Phycology, 26, 
151–161. 
Custódio, L.; Soares, F.; Pereira, H.; Rodrigues, M. J.; Barreira, L.; Rauter, A.P.; Alberício, 
F. & Varela, J. (2015). Botryococcus braunii and Nannochloropsis oculata extracts 
inhibit cholinesterases and protect human dopaminergic SH-SY5Y cells from H2O2-
induced cytotoxicity. Journal of Applied Phycology, 27, 839-848 
Custódio, L.; Laukaityte, S.; Engelen, A. H.; Rodrigues, M. J.; Pereira, H.; Vizetto-Duarte 
C.; Barreira, L.; Rodríguez, H.; Alberício, F. and Varela, J. (2016). A comparative 
evaluation of biological activities and bioactive compounds of the seagrasses 
Zostera marina and Z. noltei from Southern Portugal. Natural Products Research, 
30, 724-8. 
Damiani, M.C.; Popovich, C.A.; Constenla, D. & Leonardi, P. I. (2010). Lipid analysis in 
Haematococcus pluvialis to assess its potential use as a biodiesel feedstock. 
Bioresource Technology, 101, 3801–3807.  
Darreh-Shori, T. & Soininen, H. (2010). Effects of cholinesterase inhibitors on the 
activities and protein levels of cholinesterases in the cerebrospinal fluid of patients 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 64 
with Alzheimer’s Disease: A review of recent clinical studies. Current Alzheimer 
Research, 7, 67–73. 
Dvir, I.; Stark, A.H. & Arad, S. (2015). A Foodomics Approach Reveals 
Hypocholesterolemic Activity of Red Microalgae. Genomics, Proteomics and 
Metabolomics in Nutraceuticals and Functional Foods, 2nd ed.; Bagchi, D., 
Swaroop, A., Bagchi, M., Eds. JohnWiley & Sons, Chichester, UK. 
Ebrahimzadeh, M.A.; Pourmorad, F. & Bekhradnia, A.R. (2008). Iron chelating activity, 
phenol and flavonoid content of some medicinal plants from Iran. African Journal 
of Biotechnology, 7, 3188–3192.   
El, S.N. & Karakaya, S. (2004). Radical scavenging and iron-chelating activities of some 
greens used as traditional dishes in Mediterranean diet. International Journal of 
Food Sciences and Nutrition, 55, 67–74.   
Ellman, G.L.; Courtney, K.D.; Andres, V. & Featherstone, R.M. (1961). A new and rapid 
colorimetric determination of acetylcholinesterase activity. Biochemistry and 
Pharmacology, 7, 88–95.  
Eom, S.-H.; Kim, Y.-M. & Kim, S.-K. (2012). Antimicrobial effect of phlorotannins from 
marine brown algae. Food and Chemical Toxicology, 50, 3251–3255.  
Ferreira, A.; Proença, C.; Serralheiro, M. & Araújo, M. (2006). The in vitro screening for 
acetylcholinesterase inhibition and antioxidant activity of medicinal plants from 
Portugal. Journal of Ethnopharmacology, 108, 31–37.  
Folmer, F.; Jaspars, M.; Dicato, M. & Diederich, M. (2010). Photosynthetic marine 
organisms as a source of anticancer compounds. Phytochemistry Reviews, 9, 557–
579.  
Gago, C.; Sousa, A.R.; Julião, M.; Miguel, G.; Antunes, D.C. & Panagopoulos, T. (2011). 
Sustainable use of energy in the storage of halophytes used for food. International 
Journal of Energy and Environment, 5, 592–599.  
Ganesan, P.; Kumar, C.S. & Bhaskar, N. (2007). Antioxidant properties of methanol 
extract and its solvent fractions obtained from selected Indian red seaweeds. 
Bioresource Technology, 99, 2717–2723.  
Gardeva, E.; Toshkova, R.; Minkova, K. & Gigova, L. (2009). Cancer protective action of 
polysaccharide derived from microalga Porphyridiumcruentum – A biological 
background. Biotechnology & Biotechnological Equipment, 23, 783–787. 
Gedaraa, S. R.; Abdel-Halima, O.B.; El-Sharkawya, S.H.; Salamaa, O.M.; Shierb, T.W. & 
Halim, A.F. (2003). Cytotoxic Hydroazulene Diterpenes from the Brown Alga 
Dictyota dichotoma. Z. Naturforsch, 58, 17–22. 
Geldmacher, D. S. (2010). Alzheimer disease prevention: Focus on cardiovascular risk, 
not amyloid? Cleveland Clinic Journal of Medicine, 77, 689–704.   
Giacobini, E. (2004). Cholinesterase inhibitors: new roles and therapeutic alternatives. 
Pharmacological Research, 50, 433–440.  
Gibbs, R. B. (2010). Estrogen Therapy and Cognition: A Review of the Cholinergic 
Hypothesis. Endocrine Reviews, 31, 224–253. 
Greig, N.H.; Utsuki, T.; Ingram, D.K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.; Mamczarz, J.; 
Holloway, H.W. & Giordano, T. (2005). Selective butyrylcholinesterase inhibition 
elevates brain acetylcholine, augments learning and lowers Alzheimer-amyloid 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 65 
peptide in rodent. The National Academy of Sciences of the USA, 102, 17213–
17218. 
Grossberg, G. T. (2003). Cholinesterase Inhibitors for the Treatment of Alzheimer’s 
disease: Getting on and Staying on. Current Therapeutic Research, 64, 216–235. 
Grosso, C.; Valentão, P.; Ferreres, F. & Andrade, P.B. (2014). Bioactive marine drugs 
and marine biomaterials for brain diseases. Marine Drugs, 12, 2539–2589. 
Guzman, S.; Gato, A. & Calleja, J. M. (2001). Antiinflammatory, analgesic and free 
radical scavenging activities of the marine microalgae Chlorella stigmatophora and 
Phaeodactylumtricornutum. Phytother, 15, 224–230. 
Hamed, I.; Özogul, F.; Özogul, Y. & Regenstein, J.M. (2015). Marine Bioactive 
Compounds and Their Health Benefits: A Review. Comprehensive Reviews in Food 
Science and Food Safety, 14, 446–465. 
Hedera, P., Fink, J. K., Bockenstedt, P. L. & Brewer, G. J. (2003). Myelopolyneuropathy 
and Pancytopenia Due to Copper Deficiency and High Zinc Levels of Unknown 
Origin. Archives of Neurology, 60, 1303–1306.  
Holden, M. & Kelly, C. (2002). Use of cholinesterase inhibitors in dementia. Advances in 
Psychiatric treatment, 8, 89–96.  
Huang, X.; Cuajungco, M.P.; Atwood, C.S.; Moir, R.D.; Tanzi, R.E. & Bush, A. I. (2000). 
Alzheimer’s Disease, b-Amyloid Protein and Zinc. The Journal of Nutrition, 130, 
1488–1492.   
Huang, W.; Qiu, C.; von Strauss, E. et al. (2004). APOE genotype, family history of 
dementia, and Alzheimer disease risk: a 6-year follow-up study. Archives of 
Neurology, 61, 1930–1934.   
Huleihel, M.; Ishanu, V.; Tal, J.; Arad, S. (2002). Activity of Porphyridium sp 
polysaccharide against Herpes simplex viruses in vitro and in vivo. Journal of 
Biochemical and Biophysical Methods, 50, 189–200.  
Jalbert, J.; Daiello, L.A. & Lapane, K.L. (2008). Dementia of the Alzheimer Type. 
Epidemiologic Reviews, 30, 15–34. 
Kannan, R.; Aderogba, M.A.; Ndhlala, A.R.; Stirk, W.A. & Staden, J.V. (2013). 
Acetylcholinesterase inhibitory activity of phlorotannins isolated from the brown 
alga, Ecklonia maxima (Osbeck) Papenfuss. Food Research International, 54, 1250–
1254.  
Kawahara, M. (2003). Aluminum-Induced Conformational Changes of β-Amyloid 
Protein and the Pathogenesis of Alzheimer’s disease. Journal of Health Science, 49, 
341–347.  
Kim, A.; Shin, T.; Lee, M.; Park, J.; Park, K.; Yoon, N. et al. (2009). Isolation and 
Identification of Phlorotannins from Ecklonia stolonifera with Antioxidant and 
Anti-inflammatory Properties. Journal of Agricultural and Food Chemistry, 57, 
3483–3489. 
Khan, S.B.; Kong, C.; Kim, J. & Kim, S. (2010). Protective Effect of Amphiroa dilatata on 
ROS Induced Oxidative Damage and MMP Expressions in HT1080 Cells. 
Biotechnology and Bioprocess Engineering, 15, 191–198.  
Kong, G.; Miles, L.A.; Crespi, G.; Morton, C.J.; Ng, H.L.; Barnham, K.J. et al. (2008). 
Copper binding to the Alzheimer’s disease amyloid precursor protein. European 
Biophysics Journal, 37, 269–79.   
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 66 
Kong, C., Kim, J.; Ahn, B.; Vo, T.; Yoon, N. & Kim, S. (2010). 1-(3,5-Dihydroxyphenoxy)-7-
(2,4,6-trihydroxyphenoxy)-2,4,9-trihydroxydibenzo-1,4-dioxin inhibits adipocyte 
differentiation of 3T3-L1 fibroblasts. Marine Biotechnology, 12, 299–307. 
Kontiza, I.; Stavri, M.; Zloh, M.; Vagias, C.; Gibbons, S. & Roussis, V. (2008). New 
metabolites with antibacterial activity from the marine angiosperm Cymodocea nodosa. 
Tetrahedron, 64, 1696–1702.  
Koschnick, T.J. & Haller, W.T. (2006). Effects of Copper Chelating Agents on Diquat 
Activity in Diquat Resistant Landoltia.  Journal of Aquatic Plant Management, 44, 
125–132.  
Koz, F.F.; Yavasoglu, N.U., Demirel, Z.; Sukatar, A. & Ozdemir, G. (2009). Antioxidant 
and Antimicrobial Activities of Codium fragile (Suringar) Hariot (Chlorophyta) 
Essential Oil and Extracts. Asian Journal of Chemistry, 21, 1197–1209.  
Ksouri, R.; Megdiche, W.; Falleh, H.; Trabelsi, N.; Boulaaba, M.; Smaoui, A. & Abdelly, C. 
(2008). Influence of biological, environmental and technical factors on phenolic 
content and antioxidant activities of Tunisian halophytes. Comptes Rendus 
Biologies, 331, 865–873. 
Ksouri, R.; Ksouri, W.M.; Jallali, I.; Debez, A.; Magné, C.; Hiroko, I. & Abdelly, C. (2012). 
Medicinal halophytes: potent source of health promoting biomolecules with 
medical, nutraceutical and food applications. Critical Reviews in Biotechnology, 32, 
289–326.  
Kuhl, D.E.; Koeppe, R.A.; Snyder, S.E.; Minoshima, S.; Frey, K.A. & Kilbourn, M.R. (2006). 
In Vivo Butyrylcholinesterase Activity Is Not Increased in Alzheimer’s Disease 
Synapses. Annals of Neurology, 59, 13–20.  
Kumar, C.S.; Sarada, D.V.; Gideon, T.P. & Rengasamy, R. (2008). Antibacterial activity of 
three South Indian seagrasses, Cymodocea serrulata, Halophila ovalis and Zostera 
capensis. World Journal of Microbiology and Biotechnology, 24, 1989–1992. 
Lee, J.; Kim, S.; Jung, W.-S.; Song, D.-G.; Um, B.-H.; Son, J.-K. & Pan, C.-H. (2012). 
Phlorofucofuroeckol-A, a potent inhibitor of aldo-keto reductase family 1 member 
B10, from the edible brown alga Eisenia bicyclis. Journal of the Korean Society for 
Applied Biological Chemistry, 55, 721–727.  
Lee, S.-H. & Jeon, Y.-J. (2013). Anti-diabetic effects of brown algae derived 
phlorotannins, marine polyphenols through diverse mechanisms. Fitoterapia, 86, 
129–136.  
Li, B.; Lu, F.; Wei, X. & Zhao, R. (2008). Fucoidan: Structure and Bioactivity. Molecules, 
13, 1671–1695. 
Lim, C.S.; Jin, D.; Sung, J.; Lee, J.; Choi, H.; Ha, I. & Han, J. (2006). Antioxidant and Anti-
inflammatory Activities of the Methanolic Extract of Neorhodomela aculeate in 
Hippocampal and Microglial Cells. Biological & Pharmaceutical Bulletin, 29, 1212–
1216.  
Lopes, G.; Sousa, C.; Silva, L.R.; Pinto, E.; Andrade, P.B.; Bernardo, J.; Mouga, T. & 
Valentão, P. (2012). Can phlorotannins purified extracts constitute a novel 
pharmacological alternative for microbial infections with associated inflammatory 
conditions? PLoS One, 7, e31145.  
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 67 
Lu, Y.; Zhai, Y.; Liu, M. & Wu, Q. (2009). Biodiesel production from algal oil using 
cassava (Manihot esculenta Crantz) as feedstock. Journal of Applied Phycology, 22, 
573–578.  
Maeda, H.; Hosokawa, M.; Sashima, T. & Miyashita, K. (2007). Dietary combination of 
fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and 
decreases blood glucose in obese/diabetic KK-Ay mice. Journal of Agricultural and 
Food Chemistry, 55, 7701–7706. 
Martins, A.; Vasas, A.; Viveiros, M.; Molnárd, J.; Hohmann, J. & Amaral, L. (2011). 
Antibacterial properties of compounds isolated from Carpobrotus edulis. 
International Journal of Antimicrobial Agents, 37, 438–444. 
Medini, F.; Bourgou, S.; Lalancette, K.; Snoussi, M.; Mkadmini, K.; Coté, I.; Abdelly, C.; 
Legault, J. & Ksouri, R. (2015). Phytochemical analysis, antioxidant, anti-
inflammatory, and anticancer activities of the halophyte Limonium densiflorum 
extracts on human cell lines and murine macrophages. South African Journal of 
Botany, 99, 158–164.  
Megías, C.; Pastor-Cavada, E.; Torres-Fuentes, C.; Girón-Calle, J.; Alaiz, M.; Jua, R. et al. 
(2009). Chelating, antioxidant and antiproliferative activity of Vicia sativa 
polyphenol extracts. European Food Research and Technology, 230, 353–359. 
Mesulam, M.; Guillozet, A.; Shaw, P. & Quinn, B. (2002). Widely spread 
butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer 
brain. Neurobiology of Disease, 9, 88–93. 
Moreau, D.; Thomas-Guyon, H.; Jacquot, C.; Jugé, M.; Culioli, G.; Ortalo-Magné, A.; 
Piovetti, L. & Roussakis, C. (2006). An extract from the brown alga Bifurcaria 
bifurcata induces irreversible arrest of cell proliferation in a non-small-cell 
bronchopulmonary carcinoma line. Journal of Applied Phycology, 18, 87–93. 
Nakano, E.; Williamson, M.P.; Williams, N.H. & Powers, H. J. (2004). Copper mediated 
LDL oxidation by homocysteine and related compounds depends largely on copper 
ligation. Biochimica et Biophysica Acta, 1688, 33–42. 
Natarajan, S.; Shanmugiahthevar, K.P. & Kasi, P.D. (2009). Cholinesterase inhibitors 
from Sargassum and Gracilaria gracilis: Seaweeds inhabiting South Indian coastal 
areas (Hare Island, Gulf of Mannar). Natural Product Research, 23, 355–369. 
Neethu, P.V.; Suthindhiran, K. & Jayasri, M.A. (2017). Antioxidant and Antiproliferative 
Activity of Asparagopsis taxiformis. Pharmacognosy Research, 9, 238–246.  
Nelson, T. J. & Alkon D. L. (2005). Oxidation of cholesterol by amyloid precursor protein 
and beta-amyloid peptide. Journal of Biological Chemistry, 280, 7377–7387. 
Nuissier, G.; Diaba, F. & Grignon-Dubois, M. (2008). Bioactive agents from beach 
waste: Syringodium flotsam evaluation as a new source of L-chiro-inositol. 
Innovative Food Science and Emerging Technologies, 9, 396–400. 
Oboh, G.; Bakare, O.O.; Ademosun, A.O.; Akinyemi, A.J. & Olasehinde, T.A. (2015) 
Inhibition of cholinesterases and some pro-oxidant induced oxidative stress in rats 
brain by two tomato (LycopersiconEsculentum) varieties. International Journal of 
Biomedical Science, 11, 48–53. 
Olasehinde, T. A.; Olaniran, A. O. & Okoh, A. I. (2017). Therapeutic potentials of 
microalgae in the treatment of Alzheimer’s Disease. Molecules, 22, 480. 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 68 
Omoruyi, B.E.; Bradley, G. & Afolayan, A.J. (2012). Antioxidant and phytochemical 
properties of Carpobrotus edulis (L.) bolus leaf used for the management of 
common infections in HIV/AIDS patients in Eastern Cape Province. BMC 
Complementary and Alternative Medicine, 12, 215. 
Orhan, I.; Sener B.; Choudhary, M.I. & Khalid, A. (2004). Acetylcholinesterase and 
butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. Journal 
of Ethnopharmacology, 91, 57–60. 
Orhan, I.; Kartal, M.; Naz, Q.; Ejaz, A.; Yilmaz, G.; Kan, Y. et al. (2006). Antioxidant and 
anticholinesterase evaluation of selected Turkish Salvia species. Food Chemistry, 
103, 1247–1254. 
Orhan, I. & Aslan, M. (2009). Appraisal of scopolamine-induced antiamnesic effect in 
mice and in vitro antiacetylcholinesterase and antioxidant activities of some 
traditionally used Lamiaceae plants. Journal of Ethnopharmacology, 122, 327–332. 
Pangestuti, R. & Kim, S. K. (2011). Neuroprotective Effects of Marine Algae. Marine 
Drugs, 9, 803–818.  
Pangestuti, R. & Kim, S. K. (2013). Marine-derived bioactive materials for 
neuroprotection. Food Science Biotechnology, 22, 1175–1186. 
Park, S.Y. & Kim, H.L. (2002). Discovery of Natural Products from Curcuma longa that 
Protect Cells from Beta-Amyloid Insult: A Drug Discovery Effort against Alzheimer’s 
Disease. Journal of Natural Products, 65, 1227–1231.  
Pereira, C.G.; Barreira, L.; Bijttebier, S.; Pieters, L.; Neves, V.; Rodrigues, M.J.; Rivas, R.; 
Varela, J. & Custódio, L. (2017a). Chemical profiling of infusions and decoctions of 
Helichrysum italicum sub sp. picardii by UHPLC-PDA-MS and in vitro biological 
activities comparatively with green tea (Camellia sinensis) and rooibos tisane 
(Aspalathus linearis). Journal of Pharmaceutical and Biomedical Analysis, 145, 
593–603. 
Pereira, C.G.; Barreira, L.; Neng, N.R.; Nogueira, J.M.F.; Marques, C.; Santos, T.F.; 
Varela, J. & Custodio, L. (2017b). Searching for new sources of innovative products 
for thefood industry within halophyte aromatic plants: in vitro antioxidant activity 
and phenolic and mineral contents of infusions and decoctions of Crithmum 
maritimum L. Food and Chemical Toxicology, 107, 581–589.  
Pereira, H.; Amaro, H.M.; Katkam, N.G.; Barreira, L.; Guedes, A.C.; Varela, J. & Malcata, 
F. X. (2013a). Microalgal Biodiesel. Air Pollution Prevention and Control: 
Bioreactors and Bioenergy, 1st Ed., John Wiley & Sons, Chichester, UK.  
Pereira, H.; Barreira, L.; Custódio, L.; Alrokayan, S.; Mouffouk, F.; Varela, J.; Abu-Salah, 
K.M. & Ben-Hamadou, R. (2013b). Isolation and fatty acid profile of selected 
microalgae strains from the Red Sea for biofuel production. Energies, 6, 2773–
2783.  
Pereira, H.; Barreira, L.; Figueiredo, F.; Custódio, L.; Vizetto-Duarte, C.; Polo, C.; Rešek, 
E.; Engelen, A.; Varela, J. (2012). Polyunsaturated fatty acids of marine 
macroalgae: potential for nutritional and pharmaceutical applications. Marine 
Drugs, 10, 1920–1935. 
Pereira, H.; Custódio, L.; Rodrigues, M. J.; Bruno de Sousa, C.; Oliveira, M.; Barreira, L.; 
Neng, N.; Nogueira, F.; Alrokayan, S.A. & Mouffouk, F. (2015). Biological activities 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 69 
and chemical composition of methanolic extracts of selected autochthonous 
microalgae strains from the Red Sea. Marine Drugs, 13, 3531–3549. 
Phinney, A.L.; Drisaldi, B.; Schmidt, S.D.; Lugowski, S.; Coronado, V.; Liang, Y.; Horne, P. 
et al. (2003). In Vivo Reduction of Amyloid-Beta by a Mutant Copper Transporter. 
Proceedings of the Association of American Physicians, 100, 14193–14198.  
Pohanka, M. (2014). Inhibitors of acetylcholinesterase and butyrylcholinesterase meet 
immunity. International Journal of Molecular Sciences, 15, 9809–9825. 
Raposo, M.F.; Morais, R.M. & Morais, A.M.M. (2013). Health applications of bioactive 
compounds from marine microalgae. Life Sci, 93, 479–486. 
Reddy, C.R.K.; Jha, B.; Fujita, Y. & Ohno, M. (2008). Seaweed micropropagation 
techniques and their potentials: An overview. Journal of Applied Phycology, 20, 
609–617.  
Reynolds, D. (1997). Apolipoprotein E. Stanislaus Journal of Biochemical Reviews. 
Stanislaus: California State University. 
Rival, S.G.; Boeriu, C.G. & Wichers H.J. (2001). Caseins and Casein Hydrolysates. 2. 
Antioxidative Properties and Relevance to Lipoxygenase Inhibition. Journal 
Agriculture Food Chemistry, 49, 295–302.  
Rocha, M.I; Rodrigues, M.J.; Pereira, C.; Pereira, H.; Silva, M.M.; Neng, N.R.; Nogueira, 
J.M.F.; Varela, J.; Barreira, L. & Custódio, L. (2017). Biochemical profile and in vitro 
neuroprotective properties of Carpobrotus edulis L., a medicinal and edible 
halophyte native to the coast of South Africa. South African Journal of Botany, 111, 
222–231.  
Rodgers, B. (2008). Alzheimer’s disease, unravelling the Mystery. U.S. Department of 
Health and Human Services, 8.  
Rodgers, J.T.; Randall, J.D.; Cahill, C.M.; Eder, P.S.; Huang, X.; Gunshin, H. et al. (2002). 
An Iron-responsive Element Type II in the 5-Untranslated Region of the 
Alzheimer’s Amyloid Precursor Protein Transcript. The Journal of Biological 
Chemistry, 277, 45518–45528. 
Rodrigues, M.J.; Gangadhar, K.N.; Duarte, C.V.; Wubshet, S.G.; Nyberg, N.T.; Barreira, 
L.; Varela, J. & Custódio, L. (2014). Maritime halophyte species from southern 
Portugal as sources of bioactive molecules. Marine Drugs, 12, 2228–2244. 
Rodrigues, M.J.; Gangadhar, K.N.; Zengin, G.; Mollica, A.; Varela, J.; Barreira, L. & 
Custódio, L. (2017). Juncaceae species as sources of innovative bioactive 
compounds for the food industry: in vitro antioxidant activity, neuroprotective 
properties and in silico studies. Food and Chemical Toxicology, 107, 590–596. 
Rodrigues, M.J.; Soszynski, A.; Martins, A.; Rauter, A.P.; Neng; N.R.; Nogueira, J.; 
Varela, J.; Barreira, L. & Custódio, L. (2015). Unravelling the antioxidant potential 
and the phenolic composition of different anatomical organs of the marine 
halophyte Limonium algarvense. Industrial Crops and Products, 77, 315–322. 
Rodríguez-Morató, J.; Xicota, L.; Fitó, M.; Farré, M.; Dierssen, M. & de la Torre, R. 
(2015). Potential role of olive oil phenolic compounds in the prevention of 
neurodegenerative diseases. Molecules, 20, 4655–4680.  
Rupérez, P.; Ahrazem, O. & J.A. Leal, (2002). Potential Antioxidant Capacity of Sulfated 
Polysaccharides from the Edible Marine Brown Seaweed Fucus vesiculosus. Journal 
of Agricultural and Food Chemistry, 50, 840–845.  
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 70 
Saiga, A.; Tanabe, S. & Nishimura, T. (2003). Antioxidant Activity of Peptides Obtained 
from Porcine Myofibrillar Proteins by Protease Treatment. Journal of Agricultural 
and Food Chemistry, 51, 3661–3667. 
Salvador, N.; Garreta, A.G.; Lavelli, L. & Ribera, M. (2007). Antimicrobial activity of 
Iberian macroalgae. Scientia Marina, 71, 101–113. 
Sathya, R.; Kanaga, N.; Sankar, P. & Jeeva, S. (2013). Antioxidant properties of 
phlorotannins from brown seaweed Cystoseira trinodis (Forsskål) C. Agardh. 
Arabian Journal of Chemistry, 10, 2608–2614.  
Sayre, L.M.; Perry, G.; Harris, P.L.; Liu, Y.; Schubert, K.A. & Smith, M.A. (2000). In situ 
oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s 
disease: a central role for bound transition metals. Journal of Neurochemistry, 74, 
270–279. 
Soragni, A.; Zambelli, B.; Mukrasch, M.D.; Biernat, J.; Jeganathan, S.; Griesinger, C.; 
Ciurli, S.; Mandelkow, E. & Zweckstetter, M. (2008). Structural Characterization of 
Binding of Cu(II) to Tau Protein. Biochemistry, 47, 10841–10851. 
Stirk, W.A.; Reinecke, D.L. & Staden, J. (2007). Seasonal variation in antifungal, 
antibacterial and acetylcholinesterase activity in seven South African seaweeds. 
Journal of Applied Phycology, 19, 271–276.  
Stuchbury, G. & Munch, G. (2005). Alzheimer’s associated inflammation, potential drug 
targets and future therapies. Journal of Neural Transmission, 112, 429–453. 
Suganthy, N.; Pandian, S.K. & Devi, K.P. (2010). Neuroprotective effect of seaweeds 
inhabiting South Indian coastal area (Hare Island, Gulf of Mannar Marine 
Biosphere Reserve): Cholinesterase inhibitory effect of Hypnea valentiae and Ulva 
reticulate. Neuroscience Letters, 468, 216–219. 
Sugiura, Y.; Matsuda, K.; Okamoto, T.; Yamada, Y.; Imai, K.; Ito, T.; Kakinuma, M. & 
Amano, H. (2009). The inhibitory effects of components from a brown alga, Eisenia 
arborea, on degranulation of mast cells and eicosanoid synthesis. Journal of 
Funcional Foods, 1, 387–393.  
Sugiura, Y.; Tanaka, R.; Katsuzaki, H.; Imai, K. & Matsushita, T. (2013). The anti-
inflammatory effects of phlorotannins from Eisenia arborea on mouse ear edema 
by inflammatory inducers. Journal of Funcional Foods, 5, 2019–2023.  
Taheri, A. (2016). Antioxidant activity in some iranian seaweed species from Chabahar. 
Iranian Journal of Fisheries Sciences, 15, 802–817. 
Taskin, E.; Caki, Z.; Ozturk, M. & Taskin, E. (2010). Assessment of in vitro antitumoral 
and antimicrobial activities of marine algae harvested from the eastern 
Mediterranean sea. African Journal of Biotechnology, 9, 4272–4277.  
Taylor, P. (1998). Development of acetylcholinesterase inhibitors in the therapy of 
Alzheimer's disease. Neurology, 50, 30–35. 
Tildesley, J.; Kennedy, O.; Perry, K.; Ballard, G.; Savelev, S.; Wesnes, A. & Scholey, B. 
(2003). Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young 
volunteers. Pharmacology, Biochemistry and Behavior, 75, 669–674. 
Tirosh, Y.A.; Amit, T.; Am, O.B.; Zheng, H.; Fridkin, M. & Youdim, M. (2007). 
Therapeutic targets and potential of the novel brain-permeable multifunctional 
iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of 
Alzheimer’s disease. Journal of Neurochemistry, 100, 490–502. 
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 71 
Thring, T.S.A. & Weitz, F.M. (2006). Medicinal plant use in the Bredasdorp/Elim region 
of the Southern Overberg in the Western Cape Province of South Africa. Journal of 
Ethnopharmacology, 103, 261–275. 
Trabelsi, L.; Chaieb, O.; Mnari, A.; Abid-Essafi, S. & Aleya, L. (2016). Partial 
characterization and antioxidant and antiproliferative activities of the aqueous 
extracellular polysaccharides from the thermophilic microalgae Graesiella sp. BMC 
Complementary and Alternative Medicine, 16, 210–220.  
Tsai, S.J.; Chao, C.Y. & Yin, M.C. (2011). Preventive and therapeutic effects of caffeic 
acid against inflammatory injury in striatum of MPTP-treated mice. European 
Journal of Pharmacology, 670, 441–447. 
Tsukui, T.; Konno, K.; Hosokawa, M.; Maeda, H.; Sashima, T. & Miyashita, K. (2007). 
Fucoxanthin and fucoxanthinol enhance the amount of docosahexaenoic acid in 
the liver of KKAy obese/diabetic mice. Journal of Agricultural and Food Chemistry, 
55, 5025–5029.  
Van der Watt, E. & Pretorius, J.C. (2001). Purification and identification of active 
antibacterial components in Carpobrotus edulis L. Journal of Ethnopharmacology, 
76, 87–91. 
Van Wyk, B.-E. (2008). A broad review of commercially important southern African 
medicinal plants. Journal of Ethnopharmacology, 119, 342–355. 
Van Wyk, B.-E.; Van Oudshoorn, B. & Gericke, N. (1997). Medicinal Plants of South 
Africa. Briza Publications, Pretoria, South Africa, p. 70. 
Ventura, Y.; Wuddineh, W.A.; Myrzabayeva, M.; Alikulov, Z.; Khozin-Goldberg, I.; 
Shpigel, M.; Samocha, T.M. & Sagi, M. (2011). Effect of seawater concentration on 
the productivity and nutritional value of annual Salicornia and perennial 
Sarcocornia halophytes as leafy vegetable crops. Scientia Horticulturae, 128, 189–
196. 
Vinutha, B.; Prashanth, D.; Salma, K.; Sreeja, S.L.; Pratiti, D.; Padmaja, R. et al. (2007). 
Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory 
activity. Journal of Ethnopharmacology, 109, 359–363. 
Vo, T. & Kim, S. (2010). Potential Anti-HIV Agents from Marine Resources: An 
Overview. Marine Drugs, 8, 2871–2892. 
Weinreb, O.; Amit, T.; Mandel, S. & Youdim M. (2009). Neuroprotective molecular 
mechanisms of (2)-epigallocatechin-3-gallate: a reflective outcome of its 
antioxidant, iron chelating and neuritogenic properties. Genes and Nutrition, 4, 
283–296. 
Willis, L.M.; Shukitt-Hale, B. & Joseph, J. A. (2009). Dietary polyunsaturated fatty acids 
improve cholinergic transmission in the aged brain. Genes Nutrition, 4, 309–314. 
Ye, H.; Wang, K.; Zhou, C.; Liu, J. & Zeng, X. (2008). Purification, antitumor and 
antioxidant activities in vitro of polysaccharides from the brown seaweed 
Sargassum pallidum. Food Chemistry, 111, 428–432. 
Yoon, N.; Chung, H.; Kim, H. & Choi, J. (2008). Acetyl- and butyrylcholinesterase 
inhibitory activities of sterols and phlorotannins from Ecklonia stolonifera. 
Fisheries Science, 74, 200–207.  
Master’s Thesis in Biological Engineering  
Searching for biocompounds in algae and seagrasses with potential use in the treatment of 
Alzheimer’s disease 
 
 72 
Yoon, N.Y.; Lee, S.; Li, Y. & Kim, S. (2009). Phlorotannins from Ishige okamurae and 
their acetyland butyrylcholinesterase inhibitory effects. Journal of Functional 
Foods, 1, 331–335. 
Zarotsky, V.; Sramek, J.J. & Cutler, N.R. (2003). Galanthamine hydrobromide: An agent 
for Alzheimer’s disease. American Journal of Health-System Pharmacy, 60, 446–
452. 
Zecca, L.; Youdim M.H.; Riederer, P.; Connor, J.R. & Crichton, R. (2004). Iron, brain 
ageing and neurodegenerative disorders. Neuroscience, 5, 863–873.   
Zubia, M.; Fabre, M.S.; Kerjean, V.; Lann, K.L.; Stiger-Pouvreau, V.; Fauchon, M. & 
Deslandes, E. (2009). Antioxidant and antitumoural activities of some Phaeophyta 
from Brittany coasts. Food Chemistry, 116, 693–701. 
Zvyagintseva, T.N.; Shevchenko, N.M.; Popivnich, I.B.; Isakov, V.; Scobun, A.S.; 
Sundukova, E.V. & Elyakova, L.A. (1999). A new procedure for the separation of 
water-soluble polysaccharides from brown seaweeds. Carbohydrate Research, 
322, 32–39. 
